The genetics of folate metabolism and maternal risk of birth of a child with Down syndrome and associated congenital heart defects

Fabio Coppedé

Almost 15 years ago it was hypothesized that polymorphisms of genes encoding enzymes involved in folate metabolism could lead to aberrant methylation of peri-centromeric regions of chromosome 21, favoring its abnormal segregation during maternal meiosis. Subsequently, more than 50 small case-control studies investigated whether or not maternal polymorphisms of folate pathway genes could be risk factors for the birth of a child with Down syndrome (DS), yielding conflicting and inconclusive results. However, recent meta-analyses of those studies suggest that at least three of those polymorphisms, namely \textit{MTHFR} 677C>T, \textit{MTRR} 66A>G, and \textit{RFC1} 80G>A, are likely to act as maternal risk factors for the birth of a child with trisomy 21, revealing also complex gene-nutrient interactions. A large-cohort study also revealed that lack of maternal folic acid supplementation at peri-conception resulted in increased risk for a DS birth due to errors occurred at maternal meiosis II in the aging oocyte, and it was shown that the methylation status of chromosome 21 peri-centromeric regions could favor recombination errors during meiosis leading to its malsegregation. In this regard, two recent case-control studies revealed association of maternal polymorphisms or haplotypes of the \textit{DNMT3B} gene, coding for an enzyme required for the regulation of DNA methylation at centromeric and peri-centromeric regions of human chromosomes, with risk of having a birth with DS. Furthermore, congenital heart defects (CHD) are found in almost a half of DS births, and increasing evidence points to a possible contribution of lack of folic acid supplementation at peri-conception, maternal polymorphisms of folate pathway genes, and resulting epigenetic modifications of several genes, at the basis of their occurrence. This review summarizes available case-control studies and literature meta-analyses in order to provide a critical and up to date overview of what we currently know in this field.

Keywords: folate, polymorphisms, Down syndrome, congenital heart defects, DNA methylation, epigenetics, \textit{MTHFR}, folic acid supplementation
**Introduction**

Two studies conducted nearly 15 years ago in North America (James et al., 1999; Hobbs et al., 2000) have suggested that polymorphisms of genes encoding enzymes involved in the folate metabolic pathway, also known as one-carbon metabolism, may be maternal risk factors for the birth of a child with Down syndrome (DS). In particular, it was hypothesized that an altered metabolism of folate, resulting from the presence of polymorphisms in metabolic genes, could lead to aberrant methylation of peri-centromeric regions of chromosome 21, favoring its abnormal segregation during maternal meiosis and leading to the formation of eggs with two copies of chromosome 21, which, if fertilized, would result in a zygote with full trisomy for chromosome 21 (James et al., 1999; Hobbs et al., 2000). Those works were followed by more than 50 small case-control studies all aimed to address this issue, listed in Table 1. Overall, most of those papers are in favor of a possible contribution of polymorphisms in folate-related genes as maternal risk factors for the birth of a child with DS, however, they are often conflicting and limited by the small sample size of case-control cohorts (Table 1). In 2009, I reviewed the literature in the field, concluding that at that time no single gene could be clearly linked to the maternal risk of birth of a child with DS, due to the relatively small sample-size and the conflicting nature of the findings among the different studies (Coppedè, 2009). I also recommended collaboration among research groups and/or literature meta-analyses in order to increase the power to detect association (Coppedè, 2009). Many papers have been produced between 2009 and present days (Table 1), and literature meta-analyses are nowadays available overall suggesting that at least three polymorphisms of folate pathway genes are likely to be associated to the maternal risk for trisomy 21 (Table 2), while an increasing number of studies also suggest complex gene-gene and gene-nutrient interactions (Tables 1, 3). However, the original hypothesis linking impaired folate metabolism and abnormal methylation levels of chromosome 21 peri-centromeric regions (James et al., 1999) has not yet been demonstrated, even if in vitro studies revealed that cells under folate deprivation increase the rate of chromosome 21 aneuploidy (Wang et al., 2004; Beetstra et al., 2005; Fenech, 2012). Folic acid is a synthetic compound, structurally similar but with higher bioavailability than naturally occurring folate, which is used in supplements and in fortified foods (Barua et al., 2014). An overview of folate metabolism, also known as one-carbon metabolism, is provided in Figure 1 that illustrates the main enzymes of the pathway whose gene polymorphisms have been investigated as potential maternal risk factors for the birth of a child with DS.

**Methods**

Major online databases, namely PubMed, Scopus, and Web of Science, were searched up to April 24, 2015 using the following terms: “folate,” “polymorphisms,” “gene variant,” “genetic variant,” “homocysteine,” “congenital heart defects,” and “Down syndrome.” Only peer-reviewed case-control studies showing demographic data of case and control mothers, and tabular data of allele and genotype frequencies, have been considered for this review and included in Tables 1, 3, 4. For articles not written in English, only those published in peer-reviewed journals with an English written abstract clearly showing all the relevant information were included. Meeting abstracts, case-reports, commentaries, academic theses, letters to the editors and review articles with no novel data, were not included. All the available meta-analyses matching the search criteria are included and listed in Table 2, providing that they were written in English language with a clear indication of inclusion and exclusion criteria, as well as available tabular data showing both overall and subgroup analyses.

**Folate Metabolism: an Overview**

Folate is the general term for a water-soluble B vitamin (vitamin B9) which is naturally found in foods such as green leafy vegetables, liver, beans, egg yolks, cereals, some citrus fruits, kiwis, and strawberries (Fenech, 2012). Dietary folates are essential for normal cell growth and replication, since they work as donors and acceptors of one-carbon units during the synthesis of nucleic acids, amino acids, and S-adenosylmethionine (SAM), the main intracellular methylating agent (Figure 1). Therefore, a folate restriction results in aberrant cell growth, impaired DNA methylation, and increases the rate of point mutations, chromosome damage, and aneuploidy (Wang et al., 2004; Beetstra et al., 2005; Fenech, 2012). Folic acid is a synthetic compound, structurally similar but with higher bioavailability than naturally occurring folate, which is used in supplements and in fortified foods (Barua et al., 2014). An overview of folate metabolism, also known as one-carbon metabolism, is provided in Figure 1 that illustrates the main enzymes of the pathway whose gene polymorphisms have been investigated as potential maternal risk factors for the birth of a child with DS.

5-Methyltetrahydrofolate (5-methylTHF) is the main form of circulating folate in the plasma and can be transported into the cells by means of folate carriers and receptors, one the best characterized being the ubiquitously expressed reduced folate carrier (RFC), coded by the SLC19A1 gene (commonly known as RFC1 gene) (Hou and Matherly, 2014). Intracellularly, 5-methylTHF functions as a methyl donor for homocysteine (hcy) remethylation, a reaction catalyzed by the methionine synthase (MTR) enzyme that transfers a methyl group from 5-methylTHF to hcy, forming tetrahydrofolate (THF) and methionine. Cobalamin (vitamin B12) is a cofactor in this reaction and methionine synthase reductase (MTRR)
TABLE 1 | Genetic association studies of folate pathway genes as maternal risk factors for having a child with Down syndrome.

| References                     | Country    | MDS/MC | Studied polymorphism/s | Significant findings                                                                 |
|--------------------------------|------------|--------|------------------------|--------------------------------------------------------------------------------------|
| James et al., 1999             | USA/Canada | 57/50  | MTHFR 677C>T           | MTHFR 677CT (OR = 2.5; 95% CI = 1.0–5.7)                                              |
|                                |            |        |                        | MTHFR 677CT + TT (OR = 2.6; 95% CI = 1.2–5.8)                                          |
| Hobbs et al., 2000             | USA/Canada | 157/144| MTHFR 677C>T MTRR 68A>G| MTHFR 677CT (OR = 1.9; 95% CI = 1.1–3.1)                                              |
|                                |            |        |                        | MTHFR 677CT + TT (OR = 1.9; 95% CI = 1.2–3.0)                                          |
|                                |            |        |                        | MTRR 66G (OR = 2.6; 95% CI = 1.3–5.0)                                                  |
|                                |            |        |                        | MTRR 66A (OR = 1.8; 95% CI = 1.0–3.1)                                                  |
|                                |            |        |                        | MTHFR 677TT or CT + MTRR 66G (OR = 4.1; 95% CI = 1.9–8.6)                              |
| O’Leary et al., 2002           | Ireland    | 48/192 | MTHFR 677C>T MTRR 66A>G| MTHFR 66AG (OR = 8.0; 95% CI = 1.9–116)                                               |
|                                |            |        |                        | MTHFR 66G (OR = 15; 95% CI = 1.4–78.6)                                                 |
|                                |            |        |                        | MTHFR 677CT or TT + MTRR 66G (OR = 3.0; 95% CI = 1.2–7.5)                              |
| Chadeaux-Vekemans et al., 2002 | France     | 85/107 | MTHFR 677C>T           | No association observed                                                                |
| Grillo et al., 2002            | Brazil     | 36/200 | MTHFR 677C>T MTHFR 1298A>C | MTHFR 677CT + MTHFR 1298AC associated with increased maternal risk OR = N.A.               |
| Stuppia et al., 2002           | Italy      | 64/112 | MTHFR 677C>T           | No association observed                                                                |
| Bosco et al., 2003             | Italy      | 63/72  | MTHFR 677C>T MTHFR 1298A>C MTRR 66A>G MTR 2756A>G | MTR 2756AG + GG (OR = 3.5; 95% CI = 1.2–10.9)                                          |
|                                |            |        |                        | MTR 2756AG + MTRR 66AG (OR = 5.0; 95% CI = 1.1–24.1)                                   |
| Takamura et al., 2004          | Japan      | 31/60  | MTHFR 677C>T           | No association observed                                                                |
| Boduroğlu et al., 2004         | Turkey     | 152/91 | MTHFR 677C>T MTHFR 1298A>C | No association observed                                                                |
| da Silva et al., 2005          | Brazil     | 154/158| MTHFR 677C>T MTHFR 1298A>C MTRR 66A>G MTR 2756A>G CBS 844 ins68 RFC1 80G>A | MTHFR 677T allele (OR = 1.4; 95% CI = 1.0–2.1)                                          |
|                                |            |        |                        | The presence of increasing numbers of the variant alleles (MTHFR 677T, MTHFR 1298C, MTR 2756G, MTRR 66G, and CBS 844ins68) increases maternal risk (OR = 1.2; 95% CI = 1.0–1.6) |
| Chango et al., 2005            | France     | 119/119| MTHFR 677C>T MTHFR 1298A>C MTRR 66A>G MTR 2756A>G CBS 844 ins68 RFC1 80G>A | No association observed                                                                |
| Acácio et al., 2005            | Brazil     | 70/88  | MTHFR 677C>T MTHFR 1298A>C | MTHFR 677CT + MTHFR 1298AC (OR = 5.7; 95% CI = 1.7–18.8)                              |
| Coppeddè et al., 2006          | Italy      | 80/111 | MTHFR 677C>T MTHFR 1298A>C RFC1 80G>A | MTHFR 677TT + RFC1 80G (OR = 6.0; 95% CI = 1.0–35.9)                                  |
|                                |            |        |                        | MTHFR 1298AA + RFC1 80GA/AA (OR = 0.4; 95% CI = 0.1–0.9)                                |
| Rai et al., 2006               | India      | 149/165| MTHFR 677C>T MTHFR 1298A>C | MTHFR 677TT (OR = 7.7; 95% CI = 1.7–35.1)                                              |
|                                |            |        |                        | MTHFR 1298CC (OR = 4.4; 95% CI = 1.4–13.3)                                             |
|                                |            |        |                        | MTHFR 677CC + MTHFR 1298CC (OR = 4.1; 95% CI = 1.2–13.7)                                |
| Scala et al., 2006            | Italy      | 94/264 | MTHFR 677C>T MTHFR 1298A>C MTRR 66A>G | MTHFR 1298C allele (OR = 1.5; 95% CI = 1.0–2.1)                                         |
|                                |            |        |                        | RFC1 80G allele (OR = 1.5; 95% CI = 1.0–2.1)                                            |
|                                |            |        |                        | MTHFR 1298CC (OR = 2.3; 95% CI = 1.1–5.3)                                              |

(Continued)
TABLE 1 | Continued

| References            | Country     | MDS/MCa | Studied polymorphism/s | Significant findings                                                                 |
|-----------------------|-------------|---------|------------------------|--------------------------------------------------------------------------------------|
|                       |             |         | RFC1 80G>A            | MTHFR 677CT (OR = 2.1; 95% CI = 1.1–3.9)                                              |
|                       |             |         | RFC1 80G>A            | MTHFR 677TT (OR = 3.4; 95% CI = 1.4–8.4)                                               |
| Wang et al., 2008     | China       | 64/70   | MTHFR 677C>T          | MTHFR 677TT (OR = 9.3; 95% CI = 2.9–29.7)                                              |
|                       |             |         | MTR 2756A>G           | MTHFR 677TT (OR = 5.2; 95% CI = 1.9–14.2)                                              |
|                       |             |         | RFC1 80G>A            | MTHFR 677TT/CT + MTRR 66GG (OR = 6.0; 95% CI = 2.0–17.5)                                 |
|                       |             |         | RFC1 80G>A            | MTHFR 66AG (OR = 2.6; 95% CI = 1.2–5.5)                                                |
|                       |             |         | RFC1 80G>A            | MTRR 66AG (OR = 2.2; 95% CI = 1.1–4.4)                                                 |
|                       |             |         | RFC1 80G>A            | MTRR 66AG/3G (OR = 2.2; 95% CI = 1.1–4.4)                                               |
|                       |             |         | THC2 776C>A           | MTR 2756AA (OR = 3.0; 95% CI = 1.0–8.5)                                                |
|                       |             |         | MTHFR 677TT + MTR 2756AA (OR = 3.0; 95% CI = 1.0–8.5)                                   |
|                       |             |         | MTR 2756AA (OR = 2.6; 95% CI = 1.2–5.5)                                                |
|                       |             |         | MTR 2756AA (OR = 2.6; 95% CI = 1.2–5.5)                                                |
|                       |             |         | MTHFR 1298AA (OR = 1.9; 95% CI = 1.1–3.5)                                               |
|                       |             |         | MTHFR 677CT or TT/MTHFR 1298AA (OR = 1.8; 95% CI = 1.1–3.5)                              |
|                       |             |         | MTHFR 677CT or TT/MTHFR 1298AA (OR = 1.8; 95% CI = 1.1–3.5)                              |

(Continued)
| References                  | Country     | MDS/MC | Studied polymorphism/s | Significant findings                                                                 |
|-----------------------------|-------------|--------|------------------------|---------------------------------------------------------------------------------------|
| Liao et al., 2010           | China       | 60/68  | MTHFR 677C>T           | MTHFR 677TT (OR = 3.5; 95% CI = 1.3–9.5)                                               |
|                             |             |        | MTRR 66A>G             | MTRR 66G (OR = 3.2; 95% CI = 1.2–8.3)                                                  |
|                             |             |        | MTR 2756A>G            | MTHFR 677 (CT or TT) + MTRR 66G (OR 9.5; 95% CI = 2.1–46.3)                            |
|                             |             |        | RFC1 80G>A             | MTHFR (CT or TT) + RFC-1 AA (OR 5.2; 95% CI = 1.7–15.9)                                |
|                             |             |        |                        | MTHFR 677CC + MTR 2756AG or GG (OR = 6.7; 95% CI = 1.2–35.0)                            |
|                             |             |        |                        | MTHFR 677 (CT or TT) + MTR 2756 AA (OR = 4.2; 95% CI = 1.5–11.6)                       |
|                             |             |        |                        | MTRR 66G + MTR 2756AA (OR = 3.0; 95% CI = 1.1–8.7)                                     |
|                             |             |        |                        | RFC1 80G AA + MTR 2756AA (OR = 2.7; 95% CI = 1.2–6.5)                                  |
| Neagos et al., 2010a        | Romania     | 26/46  | RFC1 80G>A             | No association observed                                                                |
| Mendes et al., 2010         | Brazil      | 105/184| DHFR 19 bp ins/del     | No association observed                                                                |
| Neagos et al., 2010b        | Romania     | 26/46  | MTHFD1 1968G>A         | No association observed                                                                |
| Coppedè et al., 2010        | Italy       | 29/32  | MTHFR 677C>T           | Artificial neural networks selected 6 variables (micronucleus frequency, MTHFR 677TT, |
|                             |             |        | MTHFR 1298A>C          | MTHFD1 1968G>A, TYMS 1494 6bp +/+ , TYMS 28 bp 3R/3R and MTR 2756AA genotypes) that  |
|                             |             |        | MTHFR 1298 (CT or TT)  | allowed to discriminate between MDS and control mothers with 90% accuracy             |
|                             |             |        | MTR 2756A>G            |                                                                                       |
|                             |             |        | RFC1 80G>A             |                                                                                       |
|                             |             |        |                        |                                                                                       |
| Vranekovic et al., 2010     | Croatia     | 111/141| MTHFR 677C>T           | No association observed                                                                |
| Sadiq et al., 2011          | Jordan      | 53/29  | MTHFR 677C>T           | MTHFR 677T allele (OR 3.1; 95% CI = 1.3–7.7)                                            |
| Marucci et al., 2012        | Brazil      | 105/185| SHMT 1420C>T           | SHMT 1420CC (OR = 0.35; 95% CI = 0.2–0.6)                                               |
|                             |             |        | SHMT 1420CT            | SHMT 1420CT (OR = 0.2; 95% CI = 0.1–0.4)                                               |
| Zampieri et al., 2012a      | Brazil      | 86/161 | MTHFD1 1968G>A         | BHMT 742AA (OR = 0.3; 95% CI = 0.1–0.9)                                                 |
|                             |             |        | BHMT 742A>G            | BHMT 742 (GA + AA) (OR = 0.6; 95% CI = 0.4–0.9)                                         |
| Zampieri et al., 2012b      | Brazil      | 105/185| MTHFR 677C>T           | MTHFR 677CT or TT (OR = 1.8; 95% CI = 1.0–3.1)                                          |
|                             |             |        | MTHFR 1298A>C          | TCN2 776GG (OR = 2.4; 95% CI = 1.0–5.8)                                                 |
|                             |             |        | MTHFR 1317T>C          | BHMT 742AA (OR = 0.3; 95% CI = 0.1–0.8)                                                 |
|                             |             |        | MTR 2756A>G            | MTHFR 677C/1298A/1317T haplotype (more frequent in control mothers P = 0.01)             |
|                             |             |        | RFC1 80G>A             |                                                                                       |
|                             |             |        | TCN2 67A>G              |                                                                                       |
|                             |             |        | CBS 844ins68           |                                                                                       |
|                             |             |        | CBS 833T>C             |                                                                                       |
|                             |             |        | MTHFD1 1968G>A         |                                                                                       |
|                             |             |        | BHMT 742G>A            |                                                                                       |
| Mohanty et al., 2012        | India       | 52/52  | MTHFR 677C>T           | No association observed                                                                |
| Tayeb, 2012                 | Saudi Arabia| 30/40 | MTHFR 677C>T           | No association observed                                                                |
| Wang et al., 2013a          | China       | 104/184| MTRR 524C>T            | MTRR 524TT (OR = 0.3; 95% CI = 0.1–0.9)                                                 |
|                             |             |        | MTRR 524 (CT + TT)     | MTRR 524 (CT + TT) (OR = 0.6; 95% CI = 0.4–1.0)                                         |
| Wang et al., 2013b          | China       | 104/184| RFC1 80G>A             | RFC1 80G allele (OR 1.5; 95% CI = 1.0–2.2)                                              |
|                             |             |        | CBS 833T>C             | CBS 833C (OR 1.5; 95% CI = 1.1–2.2)                                                     |
|                             |             |        | RFC1 80G + CBS 833TC   | RFC1 80G + CBS 833TC (OR 4.8; 95% CI = 1.8–12.7)                                        |

(Continued)
is required for the maintenance of MTR in its active state (Guéant et al., 2013). The MTR enzyme is ubiquitously expressed, whereas another hcy remethylation system, mainly expressed in the liver and in the kidneys, involves the betaine-homocysteine methyltransferase (BHMT) enzyme (Obeid, 2013).

Methionine is then converted to SAM by methionine adenosyltransferase, and most of the SAM generated is used in transmethylation reactions whereby it is converted to S-adenosylhomocysteine (SAH) by transferring the methyl group to diverse biological acceptors, including proteins and DNA. When the DNA is the final acceptor of the methyl group, the reaction is catalyzed by DNA methyltransferases (DNMTs). SAH is then converted to hcy and adenosine by SAH hydrolase (Blom and Smulders, 2011). If not converted into methionine, hcy can enter the transsulfuration pathway and be condensed with serine to form cystathionine in a reaction catalyzed by cystathionine β-synthase (CBS), which requires vitamin B6 as a cofactor. Cystathionine is then hydrolyzed to cysteine that, apart from its role in protein synthesis, is the precursor of the antioxidant compound glutathione (GSH) (Blom and Smulders, 2011).

The folate pathway is also pivotal for the synthesis of nucleic acid precursors, and THF, resulting from the reaction catalyzed by MTR, can be directly converted into 5,10-methylTHF by the action of serine hydroxymethyltransferase (SHMT). Depending on cellular demands, 5,10-methylTHF can be used for thymidylate synthesis, for purine synthesis, or for the production of 5-methylTHF required for hcy remethylation reactions (Figure 1). The tri-functional enzyme methylenetetrahydrofolate dehydrogenase (MTHFD1) interconverts THF derivatives for purine, methionine and thymidylate synthesis. The enzyme consists of three activities: 5,10-methylTHF dehydrogenase, 5,10-methenylTHF cyclohydrolase, and 10-formylTHF synthetase, and catalyzes three sequential reactions in the interconversion of THF derivatives. Once generated by the 10-formylTHF synthetase activity, 10-formylTHF can donate one-carbon groups for the production of 5-methylTHF required for hcy remethylation reactions. THF is then

| References | Country | MDS/MC | Studied polymorphism/s | Significant findings |
|------------|---------|--------|------------------------|----------------------|
| Amorim et al., 2013 | Brazil | 94/134 | BHMT 742G>A | BHMT 742A (OR = 0.6; 95% CI = 0.4–0.9) BHMT 742AA (OR = 0.2; 95% CI = 0.04–0.8) |
| Coppedè et al., 2013a | Italy | 286/305 | MTR 2756A>G | No association observed |
| Coppedè et al., 2013b | Italy | 172/157 | DNMT3B –579G>T DNMT3B –149C>T | DNMT3B –579T (OR 0.7; 95% CI = 0.5–0.9) DNMT3B –579GT (OR 0.5; 95% CI = 0.3–0.9) DNMT3B –579 (GT+T) (OR 0.5; 95% CI = 0.3–0.9) DNMT3B –579GT + DNMT3B –149CC (OR = 0.2; 95% CI = 0.1–0.6) |
| Kaur and Kaur, 2013 | India | 110/111 | MTHFR 677C>T | No association observed |
| Cretu et al., 2013 | Romania | 26/46 | CBS 844ins68 | No association observed |
| Pandey et al., 2013 | India | 80/100 | MTHFR 677C>T MTHFR 1298A>C | MTHFR 1298 (AC+CC) (OR = 3.1, 95% CI 1.6–5.8) |
| Liao et al., 2014 | China | 76/115 | MTHFD1 1958G>A TCN2 776C>G | MTHFR 677CT/TT + MTHFD1 1958AA/GA (OR = 3.1; 95% CI = 1.1–9.0) TCN2 776CG + MTHFR 677TT (OR = 3.6; 95% CI = 1.3–10.3) MTHFR data taken from Liao et al. (2010) |
| Coppedè et al., 2014 | Italy | 253/298 | MTRR 66A>G | MTR 2756AG + MTRR 66AG (OR 1.8; 95% CI = 1.0–3.2) MTR data taken from Coppedè et al. (2013a) |
| Jaiswal et al., 2015 | India | 150/172 | DNMT3B –579G>T DNMT3B –149C>T | Significant increased frequency of the -579G/-149T haplotype in case mothers (P = 0.002) |
| Izci Ay et al., 2015 | Turkey | 47/49 | MTHFR 677C>T MTHFR 1298A>C MTRR 66A>G RFC1 80G>A CBS 844ins68 MTHFD1 1958G>A | MTHFR 677C allele (OR = 0.5; 95% CI = 0.26–0.96) MTHFD1 1958A allele (OR =1.9; 95% CI =1.1–3.3) |

*MDS, mothers of Down syndrome individuals; MC, control mothers.*
| References | Meta-analyses of studies linking polymorphisms of folate pathway genes to the maternal risk for having a birth with Down syndrome. |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------|
| **Table 2**     |                                                                                                                                 |
| **Studied polymorphism/s** | **Overall findings (Significant data are in bold)** | **Subgroup analysis (Significant data are in bold)** |
| **MDS/MC**       | **Allele contrast (OR)** | **WT vs. CC (OR)** | **CT vs. CC (OR)** | **CT vs. CC (OR)** |
| **Zintzaras, 2007** | Allele contrast OR = 1.18; 95% CI = 0.96–1.49 | Dominant OR = 1.06; 95% CI = 0.83–1.35 | Reccessive OR = 1.06; 95% CI = 0.83–1.35 |
| **Medina et al., 2000** | Allele contrast OR = 1.03; 95% CI = 0.90–1.17 | Dominant OR = 1.07; 95% CI = 0.89–1.27 | Reccessive OR = 1.07; 95% CI = 0.89–1.27 |
| **Costa-Lima et al., 2013** | Allele contrast OR = 1.23; 95% CI = 1.02–1.49 | Dominant OR = 1.26; 95% CI = 1.12–1.51 | Reccessive OR = 1.26; 95% CI = 1.12–1.51 |
| **Wu et al., 2013** | Allele contrast OR = 1.22; 95% CI = 1.06–1.38 | Dominant OR = 1.23; 95% CI = 1.09–1.38 | Reccessive OR = 1.23; 95% CI = 1.09–1.38 |
| **Coppedè et al., 2013a** | Allele contrast OR = 1.21; 95% CI = 1.15–1.29 | Dominant OR = 1.21; 95% CI = 1.15–1.29 | Reccessive OR = 1.21; 95% CI = 1.15–1.29 |
| **Coppedè et al., 2013c** | Allele contrast OR = 1.19; 95% CI = 1.06–1.33 | Dominant OR = 1.19; 95% CI = 1.06–1.33 | Reccessive OR = 1.19; 95% CI = 1.06–1.33 |
| **Coppedè et al., 2013b** | Allele contrast OR = 1.17; 95% CI = 1.12–1.23 | Dominant OR = 1.17; 95% CI = 1.12–1.23 | Reccessive OR = 1.17; 95% CI = 1.12–1.23 |

(Continued)
TABLE 2 | Continued

| References          | MDS/MC a | Studied polymorphism/s | Overall findings (Significant data are in bold) | Subgroup analysis (Significant data are in bold) |
|---------------------|----------|------------------------|-------------------------------------------------|-------------------------------------------------|
| Yang et al., 2013   | 2.458/3.144 | MTHFR 677C>T           | Allele contrast (OR = 1.28; 95% CI =1.11–1.47)   | Caucasians1 (OR = 1.15; 95% CI = 1.03–1.29) Asians1 (OR = 1.68; 95% CI = 1.08–2.63) Others1 (OR = 1.02; 95% CI = 1.02–1.43) |
|                     | 1.664/2.027 | MTHFR 1298A>C          | Allele contrast (OR = 1.16; 95% CI = 0.98–1.36)   | Caucasians1 (OR = 1.03; 95% CI = 0.83–1.29) Asians1 (OR = 1.41; 95% CI = 0.88–2.27) Others1 (OR = 1.28; 95% CI = 0.94–1.74) |
|                     | 1.478/2.037 | MTRR 66A>G             | Allele contrast (OR = 1.22; 95% CI = 1.02–1.46)   | Caucasians1 (OR = 1.24; 95% CI = 0.98–1.58) Asians1 (OR = 1.57; 95% CI = 0.94–2.60) Others1 (OR = 1.01; 95% CI = 0.86–1.19) |
|                     | 1.038/1.286 | MTR 2756A>G            | Allele contrast (OR = 1.07; 95% CI = 0.91–1.25)   | Caucasians1 (OR = 0.99; 95% CI = 0.77–1.29) Asians1 (OR = 0.74; 95% CI = 0.29–1.87) Others1 (OR = 1.13; 95% CI = 0.92–1.38) |
|                     | 0.629/1.249 | RFC1 80G>A             | Allele contrast (OR = 1.16; 95% CI = 1.02–1.31)   | Caucasians1 (OR = 1.21; 95% CI = 0.98–1.58) Asians1 (OR = 0.99; 95% CI = 0.43–2.33) Others1 (OR = 1.14; 95% CI = 0.95–1.38) |
|                     | 0.825/1.034 | CBS 844 ins68          | Allele contrast (OR = 1.03; 95% CI = 0.82–1.29)   | Caucasians1 (OR = 0.78; 95% CI = 0.46–1.33) Asians1 N.A. Others1 (OR = 1.09; 95% CI = 0.85–1.40) |
| Coppedè et al., 2014| 1.171/1.402 | MTRR 66A>G             | Allele contrast (OR = 1.26; 95% CI = 1.04–1.51)   | Europeans9 (OR = 1.22; 95% CI = 0.96–1.55) Not Europeans9 (OR = 1.36; 95% CI = 0.94–1.96) Mediterraneans9 (OR = 1.10; 95% CI = 0.94–1.29) |
|                     |           |                       | Dominant (OR = 1.36; 95% CI = 1.10–1.68)          | Europeans2 (OR = 1.31; 95% CI = 1.01–1.70) Not Europeans2 (OR = 1.47; 95% CI = 1.02–2.11) |
|                     |           |                       | Recessive (OR = 1.32; 95% CI = 1.09–1.62)         | Mediterraneans9 (OR = 1.19; 95% CI = 0.91–1.55) Europeans9 (OR = 1.25; 95% CI = 0.97–1.59) Not Europeans2 (OR = 1.48; 95% CI = 1.06–2.07) |
|                      |           |                       |                                                | Mediterraneans9 (OR = 1.11; 95% CI = 0.85–1.46) |
| Victorino et al., 2014| 2.223/2.807 | MTHFR 677C>T           | Allele contrast (OR = 1.25; 95% CI = 1.09–1.44)   | Caucasians1 (OR = 1.17; 95% CI = 1.04–1.31) Asians1 (OR = 1.95; 95% CI = 1.04–1.43) Brazilians1 (OR = 1.22; 95% CI = 1.05–1.64) |
|                     |           |                       | TT vs. CC (OR = 1.46; 95% CI = 1.10–1.94)         | Caucasians1 (OR = 1.28; 95% CI = 1.00–1.65) Asians1 (OR = 2.49; 95% CI = 0.24–25.8) Brazilians1 (OR = 1.38; 95% CI = 0.95–2.02) |
|                     |           |                       | CT vs. CC (OR = 1.27; 95% CI = 1.07–1.52)         | Caucasians1 (OR = 1.20; 95% CI = 0.93–1.54) Asians1 (OR = 1.46; 95% CI = 1.05–2.03) Brazilians1 (OR = 1.30; 95% CI = 1.04–1.62) |
|                     | 1.601/1.849 | MTHFR 1298A>C          | Allele contrast (OR = 1.06; 95% CI = 0.91–1.24)   | Caucasians1 (OR = 1.04; 95% CI = 0.81–1.33) Asians1 (OR = 1.32; 95% CI = 0.92–1.90) Brazilians1 (OR = 1.02; 95% CI = 0.86–1.22) |

(Continued)
### TABLE 2 | Continued

| References                     | MDS/MC | Studied polymorphism/s | Overall findings (Significant data are in bold) | Subgroup analysis (Significant data are in bold) |
|--------------------------------|--------|------------------------|-------------------------------------------------|-------------------------------------------------|
| Rai et al., 2014               | 3.098/4.852 | MTHFR 677C>T          | Allele contrast (OR = 1.22; 95% CI = 1.13–1.31) | Asians (OR = 1.53; 95% CI = 1.29–1.82)          |
|                               |        |                        |                                                 | Americans (OR = 1.23; 95% CI = 1.07–1.39)       |
|                               |        |                        |                                                 | Europeans (OR = 1.04; 95% CI = 0.93–1.16)       |
| Balduino Victorino et al., 2014 | 1.311/1.674 | MTR 2756A>G           | Allele contrast (OR = 1.11; 95% CI = 0.97–1.26) | Caucasians (OR = 1.04; 95% CI = 0.83–1.31)       |
|                               |        |                        |                                                 | Brazilians (OR = 1.14; 95% CI = 0.96–1.34)       |
|                               | 1.486/2.163 | MTRR 66 A>G           | Allele contrast (OR = 1.18; 95% CI = 0.99–1.40) | Caucasians (OR = 1.26; 95% CI = 0.96–1.66)       |
|                               |        |                        |                                                 | Brazilians (OR = 1.00; 95% CI = 0.88–1.14)       |
|                               |        |                        | Dominant (OR = 1.29; 95% CI = 1.09–1.53)       | Caucasian (OR = 1.42; 95% CI = 1.08–1.88)       |
|                               |        |                        |                                                 | Brazilian (OR = 1.14; 95% CI = 0.91–1.42)        |
|                               |        |                        | Recessive (OR = 1.33; 95% CI = 1.03–1.71)      | Caucasian (OR = 1.43; 95% CI = 1.13–1.83)       |
|                               |        |                        |                                                 | Brazilian (OR = 1.02; 95% CI = 0.86–1.22)        |
|                               | 825/1034 | CBS 844ins68          | Allele contrast (OR = 1.07; 95% CI = 0.86–1.34) | Brazilian (OR = 1.07; 95% CI = 0.83–1.37)       |
|                               | 497/900  | MTHFD1 1958G>A        | GA vs. GG (OR = 1.33; 95% CI = 1.01–1.75)      | N.A.                                            |
|                               | 496/743  | TCN2 776C>G           | Allele contrast (OR = 1.27; 95% CI = 0.83–1.93) | N.A.                                            |

---

* MDS, mothers of Down syndrome individuals; MC, control mothers.

b Caucasian inhabitants of Europe and North America. Studies in Asian populations, in mixed Brazilian populations, or in inhabitants of the Middle East were scarce for subgrouping.

c Tropical Regions: between 23.5° North (N) and 23.5° South (S); Sub-Tropical Regions: between 23.5° and 40° N/S; Northern Region: ≥ 40° N.

d The authors included in the “Caucasians” subgroup both Europeans, North Americans and inhabitants of the Middle East. Brazilian studies conducted either in mixed Brazilian populations or in individuals of European descent were subgrouped as “Others.”

e The “Caucasian” subgroup was composed by studies performed in Europeans; the Brazilian subgroup was composed by studies performed in mixed Brazilian populations.

f The authors included in the “Caucasians” subgroup both Europeans, North Americans and inhabitants of the Middle East. Brazilian studies conducted either in mixed Brazilian populations or in individuals of European descent were subgrouped as “Brazilians.”

g This study was restricted to Caucasians that were subgrouped as follows: Europeans, all the Europeans; Not Europeans, Americans of European descent; Mediterraneans, European inhabitants of Mediterranean regions.

h Similar results observed for dominant, recessive, and/or co-dominant models.
| References               | Country   | MDS/MC | Studied markers of one-carbon metabolism | Studied polymorphism/s | Main findings                                                                                                                                 |
|--------------------------|-----------|--------|-----------------------------------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------|
| James et al., 1999       | USA/Canada | 57/50  | Plasma hcy                              | MTHFR 677C>T           | Increased hcy levels in MDS. Increased hcy/methionine ratio in MDS. Increased hcy levels in MDS carriers of the MTHFR 677CT or TT genotype. Folate intake from foods was significantly lower than the recommended daily allowance in MDS at conception. Increased reported alcohol intake at conception in MDS. |
| O’Leary et al., 2002     | Ireland   | 48/192 | Plasma hcy                              | MTHFR 677C>T           | No difference in hcy levels between MDS and control mothers. Increased hcy levels in control mothers carriers of the MTHFR 677TT genotype. Plasma folate and vitamin B12 levels resulted significant predictors of hcy levels. |
| Chadefaux-Vekemans et al., 2002 | France  | 85/107 | Plasma hcy                              | MTHFR 677C>T           | No difference in hcy levels between MDS and control mothers. No difference in hcy levels according to MTHFR 677C>T genotypes. |
| Bosco et al., 2003       | Italy     | 63/72  | Plasma hcy                              | MTHFR 677C>T MTHFR 1298A>C MTRR 66A>G MTR 2756A>G | Increased hcy levels in MDS. No difference in folate or vitamin B12 levels between MDS and control mothers. No interaction between hcy, folate or vitamin B12 levels and the studied polymorphisms. |
| Takamura et al., 2004    | Japan     | 31/60  | Plasma hcy                              | MTHFR 677C>T           | Increased hcy levels in MDS. Decreased serum folate levels in MDS. No difference in vitamin B6 or B12 levels between MDS and control mothers. No interaction between the MTHFR 677C>T polymorphism and markers of one-carbon metabolism. |
| da Silva et al., 2005    | Brazil    | 154/158| Plasma hcy                              | MTHFR 677C>T MTHFR 1298A>C MTRR 66A>G MTR 2756A>G CBS 844 ins68 | Increased hcy levels in MDS. Increased hcy levels in MDS carriers of the MTHFR 677TT genotype. |
| Scala et al., 2006       | Italy     | 94/264 | Plasma hcy                              | MTHFR 677C>T           | No difference in hcy levels between MDS and control mothers. No interaction between hcy levels and the studied polymorphisms. |
| Martinez-Frias et al., 2006 | Spain   | 91/90  | Plasma hcy                              | MTHFR 677C>T           | Increased hcy levels in MDS. The MTHFR 1298A>C polymorphism was associated with hcy levels. Interactions between MTHFR 1298A>C and MTRR 66A>G polymorphisms affect hcy levels, but in different ways in MDS than in control mothers. |

(Continued)
| References     | Country     | MDS/MC<sup>a</sup> | Studied markers of one-carbon metabolism | Studied polymorphism/s | Main findings                                                                 |
|----------------|-------------|--------------------|----------------------------------------|------------------------|-------------------------------------------------------------------------------|
| Wang et al., 2007 | China       | 100/100            | Plasma hcy                             | MTHFR 677C>T           | Increased hcy levels in MDS. Increased hcy levels in carriers of MTHFR 677CT or TT genotypes. |
| Meguid et al., 2008 | Egypt       | 42/48              | Folate intake<sup>b</sup>               | MTHFR 677C>T, MTHFR 1298A>C | Folate intake from foods was significantly lower than the recommended daily allowance in MDS. |
| Braseli et al., 2008<sup>b</sup> | Brazil     | 58/49              | Plasma hcy                             | MTHFR 677C>T, MTHFR 1298A>C, MTR 2756A>G, RFC1 80A>G | Increased hcy levels in MDS. Interaction between hcy levels and the MTHFR 1298A>C polymorphism: hcy levels were higher in MDS carriers of the MTHFR 1298CC genotype, but the same genotype resulted in lower hcy levels in control mothers. |
| Kohli et al., 2008 | India       | 92/91              | Plasma hcy, Folate intake<sup>b</sup>   | MTHFR 677C>T           | Decreased hcy levels in MDS.                                                   |
| Santos-Rebouças et al., 2008 | Brazil       | 103/108            | Folate intake<sup>b</sup>, Methionine<sup>b</sup>, Vitamin B6<sup>b</sup>, Vitamin B12<sup>b</sup>, Vitamin B12<sup>b</sup> | MTHFR 677C>T, MTHFR 1298A>C, MTRR 66A>G | Folate intake from foods was significantly lower than the recommended daily allowance in both MDS and control mothers. MDS had an estimate lower intake of zinc and methionine respect to control mothers. |
| Mohanty et al., 2012 | India       | 52/52              | Plasma hcy, Serum folate, Vitamin B12, RBC folate<sup>c</sup> | MTHFR 677C>T           | Decreased serum folate levels and trend for decreased RBC folate in MDS. |
| Mendes et al., 2010; Marucci et al., 2012; Zampiet et al., 2012<sup>a,b</sup> | Brazil(São Paulo) | 105/185            | Plasma hcy, Serum folate, Plasma MMA<sup>d</sup> | MTHFR 677C>T, MTHFR 1298A>C, MTHFR 1317T>C, MTR 2756A>G, MTRR 66A>G, RFC1 80G>A, TCN2 67A>G, TCN2 776G>G, CBS 844ins68, CBS 833T>C, MTHFD1 1958G>A, BHMT 742G>A, DHFR 19bp ins/del, SHMT 1420C>T | MTHFR 677CT or TT genotypes were associated with plasma folate levels below the 25<sup>th</sup> percentile. RFC1 80GG genotype was associated with plasma folate levels below the 25<sup>th</sup> percentile only in women aged < 35 years at conception. MTRR 66AG or GG genotypes were associated with MMA concentrations above the 75<sup>th</sup> percentile. |
| Wang et al., 2013a | China       | 104/184            | Plasma hcy, Serum folate                | MTRR 524C>T           | Increased hcy levels in MDS. The MTRR 524TT genotype was associated with low hcy levels in MDS. |

<sup>a</sup>MDS, myelodysplastic syndrome; MC, maternal control; hcy, homocysteine; <sup>b</sup>b, blood; <sup>c</sup>c, cord blood; <sup>d</sup>d, DNA; <sup>e</sup>e, RNA.
reduced back to THF by dihydrofolate reductase (DHFR) (Coppedè, 2009). However, 5,10-methyleneTHF can also be reduced to 5-methylTHF by methylenetetrahydrofolate reductase (MTHFR), a vitamin B2 (riboflavin) dependent enzyme, which is of great importance for the regulation of available folate derivatives for homocysteine remethylation and DNA methylation reactions (Martínez-Frías, 2008).

The one-carbon metabolic pathway is tightly regulated by intracellular levels of metabolites and cofactors, such as high intracellular SAM levels that activate CBS and inhibit MTHFR, thus shifting hcy levels from transmethylation toward transsulfuration reactions (Finkelstein, 2007). Cobalamin, riboflavin, and vitamin B6 are required as cofactors of several enzymes of the pathway (Figure 1), and their bioavailability is essential for their function, such as for example in the case of vitamin B12 which is a cofactor of MTR in the synthesis of methionine (Guéant et al., 2013). Also cobalamin is obtained from the diet, mainly from meat, eggs, and shellfish, and the absorbed cobalamin forms a complex with transcobalamin (TC, formerly known as transcobalamin II) that transports the vitamin from the bloodstream to the tissues, were cell surface receptors allow it to enter the cells (Fedosov, 2012). The TCN2 gene codes for TC, and also TCN2 polymorphisms have been investigated as potential maternal risk factors for the birth of a DS child (Table 1).

The Biology of Human Female Meiosis, the Origin of Chromosome 21 Malsegregation, and the Potential Contribution of Dietary Folate Availability

In females of the human species, primordial oocytes enter meiosis I (MI) during fetal development, undergo DNA replication and homologous recombination, and then remain arrested in prophase I (dictyotene stage) for several years until ovulation. Meiosis II (MII) is completed only after fertilization that can occur from almost 13 to more than 40 years after the initiation of meiosis I. Advanced maternal age at conception and impaired chromosome 21 recombination represent the two best-known maternal risk factors for chromosome 21 non-disjunction (Lamb et al., 1997; Oliver et al., 2008). Particularly, MI errors are associated with the absence of recombination or with the presence of a single event near the telomere of 21q (Warren et al., 1987; Lamb et al., 1997), and these associations appear to be independent of the age of the oocyte (Oliver et al., 2012). By contrast, MII errors are associated with recombination occurring near the centromere of 21q (Lamb et al., 1997), which appears to depend on the increasing age of the oocyte (Oliver et al., 2012). In this regard it was recently observed that genomic features that affect the accessibility of a specific chromosome region to recombination, including GC content and CpG fraction, are altered in at least a proportion of oocytes with MI and MII errors, and particularly in those with recombinant events occurring in proximal regions, suggesting that factors characteristic of peri-centromeric DNA such as chromatin structure or epigenetic modifications may affect the...
accessibility of a specific chromosome region to recombination in at least a proportion of oocytes with meiotic errors (Oliver et al., 2014). Interestingly, a recent screening of more than 20,000 oocytes revealed that most of trisomy 21 cases are due to errors occurred at maternal MI or to sequential MI and MII errors, and should be therefore linked to recombination errors that occurred or initiated during the fetal development of the mother in the maternal grandmother’s body (Kuliev et al., 2011). However, more than 35% of the cases were due to maternal MII errors, occurring in adult life. In addition, not all trisomy 21 embryos survive up to the birth, and the aneuploid embryo survival might also depend on the meiotic origin of the error (Kuliev et al., 2011).

Despite that inadequate folate intake or impaired metabolism can account for genomic features resulting in aberrant chromosome 21 recombination and malsegregation (Fenech, 2012), we must take into account that, if it is the number and location of the chiasma between the chromosome 21 homologs that predispose to either MI or MII errors, the predisposition for most chromosome 21 meiotic errors may be set during the prophase of the first meiotic division, during the mother’s fetal development in the maternal grandmother’s body (Lamb et al., 1997; Coppè, 2009; Oliver et al., 2012). Therefore, the maternal risk for chromosome 21 malsegregation could be the result of a complex gene-environment interaction involving the maternal grandmother’s diet, lifestyles, and genotype and the maternal genotype (Figure 2). Also the maternal diet at peri-conception, that provides dietary folates for the completion of the meiotic process, could be of relevance for chromosome 21 malsegregation (Figure 2). In this regard a recent population-based case-control study compared the use of folic acid-containing supplements among 702 mothers of infants with full trisomy 21 due to maternal nondisjunction and 983 mothers of infants born with no major birth defects. The study revealed that lack of folic acid supplementation during pregnancy might be associated specifically with MII errors in the aging oocyte (OR = 2.00; 95% CI = 1.25–4.09).

### TABLE 4 | Genetic association studies of folate pathway genes as risk factors for having a child with Down syndrome and congenital heart defects.

| References                | Country | Cases                                                                 | Studied polymorphism/s | Main findings                                                                 |
|---------------------------|---------|----------------------------------------------------------------------|------------------------|-----------------------------------------------------------------------------|
| Brandalize et al., 2009   | Brazil  | 239 MDS, 90 of DS-CHD, 149 of DS without CHD, 16 of DS with GI disease | MTHFR 677C>T, MTHFR 1298A>C | MTHFR 677CT or TT increased the risk for CHD: All MDS (OR = 2.07; 95% CI = 1.18–3.61), non users of folic acid supplements: (OR = 2.26; 95% CI = 1.25–4.09), users of folic acid supplements (OR = 1.07; 95% CI = 0.20–5.68). No association of CHD with the MTHFR 1298A>C polymorphism. No association of the studied polymorphisms with GI disease risk. |
| Locke et al., 2010        | USA     | 121 case families: (mother, father, proband with DS-CHD), 122 control families: (mother, father, proband with DS and no CHD) | 45 single nucleotide polymorphisms (SNPs) of: MTHFR, MTR, MTRR, RFC1, and CBS genes | Several RFC1 SNPs showed association with CHD (AVSD): ORs ranging from 1.3 to 3.8 depending on the model considered. The MTHFR 1298A allele was over-transmitted to DS-AVSD individuals and under-transmitted to those with no CHD. |
| Božović et al., 2011      | Croatia | 112 DS individuals: (54 DS-CHD and 58 DS without CHD), 221 healthy controls, 107 MDS, 34 triads: (mother, father, proband) | MTHFR 677C>T, MTHFR 1298A>C | No difference in allele or genotype frequencies between DS-CHD cases and DS cases without CHD, no difference between DS cases and controls, and no association between the presence of either MTHFR 677C>T or MTHFR 1298A>C polymorphisms in the mother and risk of having a child with DS-CHD. |
| Elsayed et al., 2014      | Egypt   | 61 mothers of CHD individuals: 25 of DS-CHD, 36 of CHD without DS, 61 control mothers: no children with DS or CHD | MTHFR 677C>T | Increased frequency of the MTHFR 677CT genotype in mothers of DS individuals with atrioventricular canal compared to control mothers (OR = 1.21; 95% CI = 1.02–1.43). |

*MDS, mothers of Down syndrome individuals.

1DS-CHD, Down syndrome individuals with congenital heart defects.

2GI disease, congenital gastrointestinal disease.

3AVSD, atrioventricular septal defect.
could be of relevance for the birth of a DS child at advanced maternal age (Hollis et al., 2013).

Collectively, the above-discussed studies suggest that a clear comprehension of the contribution of genetic polymorphisms in folate-pathway genes to the maternal risk of birth of a child with DS should take into account the origin of the meiotic error and, possibly, the dietary habits and lifestyles of at least two generations, i.e., the mother and the maternal grandmother (Figure 2). Unfortunately, those data are largely missing from the studies listed in Table 1, so that at present no meta-analysis of those studies (Table 2) could stratify the data according to MI or MII errors or to maternal age at conception. For what instead concerns the maternal grandmother’s diet, only well designed prospective studies will help us to understand if there is a decreased risk for DS in the grandchildren of women taking folic acid supplements.

Maternal Folate Metabolism and the Survival of a Trisomic DS Embryo
For what instead concerns the possibility that a trisomic DS embryo will survive up to the birth, a complex maternal-embryonic interaction involving folate metabolism was proposed (Martínez-Frías et al., 2006): Particularly, since many genes involved in folate metabolism map to chromosome 21, including RFC1, CBS, and others, it was hypothesized that embryos with full trisomy 21 might have a different folate demand than normal embryos, and that maternal folate intake during pregnancy, maternal genotype for genes of the folate metabolic pathway, as well as genotype and expression levels of folate pathway genes mapping to chromosome 21 in the DS embryo, could interact to determine death in utero or survival up to the birth (Martínez-Frías et al., 2006) (Figure 2). This is a very interesting hypothesis, but we lack data of comparison between mothers of living DS individuals and women who experience loss of trisomy 21 pregnancies in order to evaluate differences in the frequency of polymorphisms of folate pathway genes between the two groups, or the preferential transmission of certain alleles to those DS embryos that reach the birth with respect to those that die in utero, so that the question is still unsolved. However, as discussed in the next sections of this paper, we cannot exclude that maternal polymorphisms of folate pathway genes, their preferential transmission to a DS embryo, as well as
epigenetic modifications and expression levels of folate-related genes mapping to chromosome 21, could contribute to the DS phenotype, including the development of congenital defects or that of other diseases later in life.

Polymorphisms of Folate Pathway Genes and Maternal Risk of Birth of a Child with DS

Methylenetetrahydrofolate Reductase (MTHFR)

MTHFR catalyzes the reduction of 5,10-methyleneTHF to 5-methylTHF, which is required for the remethylation of hcy to methionine (Figure 1). A common MTHFR 677C>T polymorphism (rs1801133), resulting in Ala222Val amino acid substitution, is known to reduce enzyme activity. Indeed, MTHFR works as a dimer protein that is stabilized by physiological levels of folate, and the MTHFR 677T allele renders the enzyme thermostable, particularly in homozygous TT individuals that are prone to dimer destabilization under conditions of reduced folate bioavailability (Guenther et al., 1999; Martínez-Frías, 2008). As a result, the MTHFR 677TT genotype has been often associated with hyperhomocysteinemia (Martínez-Frías, 2008). In 1999, James and coworkers reported increased plasma hcy levels and an increased frequency of both MTHFR 677CT and TT genotypes in mothers of DS individuals (MDS) with respect to control mothers, and that paper opened the way to the study of folate gene polymorphisms as maternal risk factors for the birth of a child with DS (James et al., 1999). To date, the MTHFR 677C>T polymorphism has been investigated in more than 30 small case-control studies as a potential maternal risk factor for having a birth with DS, yielding conflicting results (Table 1). The first meta-analysis, performed in 2007 to overcome the limits of small case-control cohorts, included 1.129 MDS and 1.489 control mothers, reported borderline results, and could neither confirm nor exclude a contribution for this polymorphism (Zintzaras, 2007), but all the subsequent meta-analyses, performed in recent years following the increasing number of available research papers, confirmed association with the maternal risk of birth of a child with DS (Table 2). Particularly, five meta-analyses have been published between 2013 and 2014 to address this issue (Costa-Lima et al., 2013; Wu et al., 2013; Yang et al., 2013; Rai et al., 2014; Victorino et al., 2014), with the most recent including data from 34 case-control studies for a total of 3.098 MDS and 4.852 control mothers (Rai et al., 2014). They mainly differ for the inclusion criteria because,
according to the author’s mother language, not only papers written in English, but also those written in Chinese or in Spanish and Portuguese languages have been included. However, all those meta-analyses agree that the overall odds ratio (OR) for the birth of a child with DS in carriers of the 677T allele ranges from 1.2 to 1.5 according to the genetic model under investigation, i.e., allele contrast, dominant, recessive, co-dominant, etc. (Table 2). The first meta-analysis in this field also provided the first attempt of data stratification into ethnic groups, and particularly the author performed a subgroup analysis in Caucasians, called “whites” in the original paper, including data from both European and North American studies and observing no significant contribution of the polymorphism in this group (Zintzaras, 2007). Data in populations from Asia, from the Middle East, or in mixed Brazilians were scarce to perform subgroup stratification at that time (Zintzaras, 2007). Subsequent data stratification into ethnic groups revealed that the risk is higher in Asians (OR of about 1.5 or higher, depending on the studied genetic model), and lower in Caucasians and/or other groups (OR usually ranging between 1.0 and 1.4) (Table 2). In those studies inhabitants of North America and of the Middle East were included together with Europeans in the Caucasian subgroup (Wu et al., 2013; Yang et al., 2013; Victorino et al., 2014). For what concerns the studies performed in Brazilian populations, all were performed in mixed Brazilian populations, with the exception of one study (Brandalize et al., 2009) that was performed in Brazilians of European descent, but they were grouped together as “Brazilians” or “others” in the meta-analyses (Wu et al., 2013; Yang et al., 2013; Victorino et al., 2014) (Table 2). Those meta-analyses also revealed that the frequency of the MTHFR 677T allele is higher in Caucasian MDS (ranging from 35.6 to 41.5%), followed by Brazilians (ranging from 33.5 to 33.9%), and lower in Asian populations (ranging from 20.0 to 32.3%) (Wu et al., 2013; Victorino et al., 2014). Moreover, when data were stratified according to the geographic origin of the mothers, rather than ethnicity, the higher risk was again observed in Asians (OR = 1.53; 95% CI = 1.29–1.82), followed by Americans (OR = 1.23; 95% CI = 1.07–1.39), and the result was not significant in Europeans (OR = 1.04; 95% CI = 0.93–1.16) (Rai et al., 2014). In that study Brazilians and North Americans were collectively subgrouped as Americans (Rai et al., 2014). Similarly, data stratification according to latitude, revealed a significant effect of the MTHFR 677C>T polymorphism in inhabitants of sub-tropical regions (both TT vs. CC and CT vs. CC carriers), followed by tropical regions (only CT vs. CC carriers), but no significant effect was observed for those living in northern regions of the globe (Costa-Lima et al., 2013). Those data reflect complex gene-environment interactions, and are likely to be the result of differences in allele frequencies among different populations coupled with different nutritional habits and exposure to environmental factors, such as sunlight radiations, that could interfere with folate bioavailability (Martinez-Frias, 2008; Coppedè, 2009; Costa-Lima et al., 2013; Rai et al., 2014). We should not forget that the effect of the mutant MTHFR 677TT genotype is exacerbated under conditions of low folate intake/bioavailability, but can be counteracted by physiological levels of folate (Martinez-Frias, 2008). Collectively those data reveal the MTHFR 677C>T polymorphism represents a weak maternal risk factor for the birth of a child with DS, particularly in those women subjected to nutritional and/or environmental factors resulting in reduced folate bioavailability. Interestingly, we observed association of the MTHFR 677C>T polymorphism with both chromosome 13 and 21 malsegregation events in lymphocytes of MDS and matched control mothers, evaluated by means of the micronucleus assay coupled with fluorescence in situ hybridization (FISH) to detect aneuploidy (Coppedè et al., 2007, 2009).

Another common MTHFR polymorphism, the MTHFR 1298A>C one (rs1801131), results in a Glu429Ala aminoacidic change and is in linkage disequilibrium with the MTHFR 677C>T one. Particularly, the MTHFR 677T-1298C haplotype is rare, and the double homozygous 677TT-1298CC genotype leads to MTHFR protein instability and inactivity, often resulting in prenatal death (Martínez-Frias, 2008). Meta-analysis data revealed that the frequency of the MTHFR 1298C allele is higher in Asians (36.0–40.0%), followed by Caucasians (33.0–35.5%) and Brazilians (23.0–25.0%) (Victorino et al., 2014). All the literature meta-analyses performed so far reveal that the MTHFR 1298A>C polymorphism is not an independent maternal risk factor for the birth of a child with DS, even after subgroup stratification for ethnicity or geographical factors (Table 2). However, several case-control studies revealed that haplotypes or combined genotypes generated by MTHFR 677C>T and 1298A>C polymorphisms increase the maternal risk for a birth of a child with trisomy 21 more than the presence of the MTHFR 677C>T one alone, strengthening the evidence of a functional interaction of both polymorphisms on protein stability and activity (Grillo et al., 2002; Acácio et al., 2005; Scala et al., 2006; Brandalize et al., 2009; Zampieri et al., 2012b).

**Methionine Synthase and Methionine Synthase Reductase (MTR and MTRR)**

MTR is a cobalamin-dependent enzyme that catalyzes the transmethylation of hcy to methionine and MTRR, a NADPH-dependent diflavin enzyme, is required for the reductive activation of MTR (Figure 1). A common MTRR 66A>G polymorphism (rs1801394), resulting in Ile22Met amino acid change, was the second polymorphism of the folate pathway, after the MTHFR 677C>T one, to be associated with the maternal risk of having a birth with DS in North American women (Hobbs et al., 2000). Subsequent research papers yielded conflicting results (Table 1), but starting from the meta-analysis conducted in 2009 by Medica and coworkers in 623 MDS and 936 control mothers (Medica et al., 2009), all the following meta-analyses confirmed association of this polymorphism with maternal risk for trisomy 21 in the offspring, with overall ORs ranging from 1.2 to 1.6 depending on the genetic model under investigation (Table 2). Subgroup stratification into ethnic groups, performed by recent meta-analyses (Baldino Victorino et al., 2014; Coppedè et al., 2014), suggests a significant effect in Caucasians under both dominant and recessive genetic models (Table 2). Particularly, for this polymorphism the frequency of the MTRR 66G allele ranges from 35.8 to 54.3% among Caucasians, from 40.0 to 48.0% in mixed Brazilian populations,
and from 41.5 to 62.5% in Asians (Wang et al., 2008; Balduino Victorino et al., 2014; Coppedè et al., 2014). Furthermore, geographic stratification among Caucasians revealed that the risk is higher in those of European descent that do not live in Europe (OR = 1.47; 95% CI = 1.02–2.11; dominant model) than in European Caucasians (OR = 1.31; 95% CI = 1.01–1.70; dominant model). Furthermore, when the analysis was restricted to the Caucasian inhabitants of Mediterranean regions no significant effect was observed (OR = 1.19; 95% CI = 0.91–1.55; dominant model), suggesting that also for this polymorphism geographic and dietary factors can counteract the negative effect of the genetic background (Coppedè et al., 2014). Recently, another MTRR polymorphism, namely MTRR 524C>T (rs1532268) resulting in Ser175Leu replacement, has been linked to the maternal risk of birth of a child with DS (Wang et al., 2013a). Particularly, the authors observed decreased maternal risk for carriers of the 524T allele that was associated with reduced hcy levels in Chinese women, but did not search for linkage or interaction with the MTRR 66A>G one (Wang et al., 2013a).

Concerning the MTR gene, the MTR 2756A>G polymorphism (rs 1805087), leading to the Asp919Gly substitution, was the third variant of the folate pathway to be associated with the maternal risk of having a birth with DS (Bosco et al., 2003). However, subsequent case-control studies failed to confirm this association (Table 1), and recent meta-analyses confirmed that the MTR 2756A>G polymorphism is not an independent maternal risk factor for a DS offspring (Yang et al., 2013; Coppedè et al., 2013a; Balduino Victorino et al., 2014). The contribution of the MTR 2756G allele to the maternal risk of birth of a child with DS was investigated mainly in European and mixed Brazilian populations, with similar reported allele frequencies of about 18–21% (Coppedè et al., 2013a), while the study by Liao et al. (2010) showed allele frequencies of less than 10% in Asians. The functional role of both MTR 2756A>G and MTRR 66A>G polymorphisms has been largely investigated with regards to their possible contribution to circulating hcy, folate, or vitamin B12 levels, yielding conflicting results (Coppedè, 2009). In this regard, we recently screened a large cohort of MDS and matched control mothers observing that the MTRR 66A>G polymorphism, but not the MTR 2756A>G one, was associated with increased serum folate levels in GG carriers (Coppedè et al., 2013a, 2014). Others, reported association of MTRR AG and GG genotypes with high methyalmalic acid (MMA) concentrations, an indicator of the vitamin B12 status, in Brazilian women (Zampieri et al., 2012b). However, when both polymorphisms were considered simultaneously, carriers of the combined MTR 2756AA/MTRR 66GG genotype showed increased serum folate levels, while carriers of the MTR 2756GG/MTRR 66AA genotype had both reduced folate and hcy levels (Coppedè et al., 2014). Several previous papers reported joint effects of polymorphisms of genes of the folate metabolic pathway to circulating levels of B vitamins, hcy or related metabolites, as well as to the overall maternal risk of birth of a child with DS; for example, complex interactions between MTRR 66A>G and MTHFR 1298A>C polymorphisms significantly affected hcy levels in Spanish MDS and control mothers (Martínez-Frias et al., 2006), and many authors reported association of combined MTHFR/MTRR or MTRR/MTR genotypes with maternal risk of birth of a DS baby (Hobbs et al., 2000; Bosco et al., 2003; Wang et al., 2008; Coppedè et al., 2009, 2014; Brandalize et al., 2010; Liao et al., 2010) (Table 1).

### Reduced Folate Carrier (RFC1)

The ubiquitously expressed RFC has unequivocally established itself as the major transport system in mammalian cells and tissues for folate cofactors (Hou and Matherly, 2014). A common RFC1 80G>A polymorphism (rs1051266), resulting in Arg27His replacement, was suggested to alter folate uptake, and the combined RFC1 80GG/MTHFR 677TT genotype was associated with increased plasma hcy levels (Chango et al., 2000). In 2006, we observed a borderline significant increased maternal risk of birth of a child with DS for carriers of the combined RFC1 80GG/MTHFR 677TT genotype, and a reduced risk for carriers of RFC1 80AA or AG/MTHFR 1298AA genotypes (Coppedè et al., 2006). Subsequent studies evaluating the possible contribution of this polymorphism to the maternal risk of having a DS child were conflicting (Table 1), but two recent meta-analyses (Yang et al., 2013; Coppedè et al., 2013c) suggest that it could represent an independent maternal DS risk factor with ORs ranging from 1.1 to 1.3 according to the model under investigation (Table 2). Moreover, despite that its functional role is still controversial, the RFC1 80G>A polymorphism has been associated with reduced red cell folate concentrations among healthy women (Stanisławska-Sachadyn et al., 2009), and with reduced serum folate concentrations in MDS (Zampieri et al., 2012b). However, less than 1.000 MDS were available for those meta-analyses, and subgroup stratification yielded inconclusive results likely because of the small case-control cohorts in each ethnic group (Coppedè et al., 2013c; Yang et al., 2013). However, RFC1 80G allele frequency resulted higher in Caucasian and Brazilian MDS (ranging between 49.0% and 54.0%) than in Asian ones (36.0–36.5%) (Coppedè et al., 2013a). Therefore, further studies are required to clarify the contribution of this polymorphism to the maternal risk of a DS birth.

### Cystathionine β-synthase (CBS)

CBS is a hemoprotein that catalyzes the condensation of hcy and serine to form cystathionine in the transsulfuration pathway (Figure 1). Concerning the CBS gene, two common polymorphisms have been investigated as maternal risk factors for the birth of a child with DS (Table 1). The first one consists of the insertion of 68-bp within exon 8 (CBS 844ins68, no rs#) that results in the duplication of a splice site at the intron7/exon 8 junction of the gene (Sperandeo et al., 1996), and two recent literature meta-analyses, both performed with 825 MDS and 1,034 control mothers, failed to find association of the CBS 844ins68 allele and maternal risk of having a DS child (Yang et al., 2013; Balduino Victorino et al., 2014). The second polymorphism, an 833T>C substitution (rs5742905) leading to an Ile278Thr replacement associated with mild hyperhomocysteinemia (Shao et al., 2005), gave conflicting results as a maternal risk factor for a DS birth in genetic association studies (Zampieri et al., 2012b; Wang et al., 2013b),
but has been investigated less extensively than the previous one and no meta-analysis is yet available.

**Methylenetetrahydrofolate Dehydrogenase (MTHFD1)**

MTHFD1 is a trifunctional enzyme of pivotal importance in the interconversion of folate cofactors for either nucleic acid synthesis or hcy remethylation reactions (Figure 1). The MTHFD1 1958G>A polymorphism (rs2236225), leading to Arg653Gln, reduces enzyme stability and activity and was first investigated as a maternal risk factor for trisomy 21 in Southern Italian women, showing association with DS risk in combination with the RFC1 80G>A polymorphism (the combined MTHFD1 1958AA/RFC1 80GG genotype) (Scala et al., 2006). Subsequent studies were conflicting (Zampieri et al., 2012a; Liao et al., 2014; Izcı Ay et al., 2015), but a recent meta-analysis of 497 MDS and 930 control mothers revealed a weak association with maternal risk of DS, but only in GA vs. GG carriers (OR = 1.33; 95% CI = 1.01–1.75) (Balduino Victorino et al., 2014). This is a very interesting data, but results are still preliminary due to the relatively small number of MDS available for the meta-analysis. Indeed, subgroup stratification was not possible (Balduino Victorino et al., 2014), making this variant a candidate allele to be investigated in further studies.

**Transcobalamin (TCN2)**

In the circulation, TC is the transport protein of cobalamin required for its cellular uptake mediated by specific membrane receptors (TCR) (Figure 1). A common TCN2 776C>G polymorphism (rs1801198), results in Arg232Pro replacement and impairs cobalamin metabolism (von Castel-Dunwoody et al., 2005). Genetic association studies revealed associations of this polymorphism with maternal risk of DS birth either alone (Zampieri et al., 2012b), or in combination with MTR (combined TCN2 776CC/MTR 2756AG genotype) (Fintelman-Rodrigues et al., 2009) or MTHFR (combined TCN2 776CG/MTHFR 677TT genotype) (Liao et al., 2014) polymorphisms. However, a recent meta-analysis of 495 MDS and 743 control mothers failed to confirm it as independent maternal risk factor for the birth of a DS baby (Balduino Victorino et al., 2014). Another TCN2 polymorphism, TCN2 67A>G (rs9606756) leading to Ile23Val substitution, was investigated only in Brazilian women and showed no association with maternal risk for a DS birth (Zampieri et al., 2012b).

**Serine-Hydroxymethyltransferase (SHMT), Thymidylate Synthase (TYMS), and Dihydrofolate Reductase (DHFR)**

SHMT uses serine as the one-carbon donor for the conversion of THF into 5,10-methyleneTHF, that can be used for thymidylate synthesis in the reaction catalyzed by TYMS that produces dTMP and DHF; which is then reduced back to THF by DHFR (Figure 1). Polymorphisms of SHMT, TYMS, and DHFR have been investigated only in one case-control study each (Coppedè et al., 2009; Mendes et al., 2010; Marucci et al., 2012) so that data are still preliminary and no meta-analysis is yet possible. Particularly, the SHMT 1420C>T polymorphism (rs1979277), that results in Leu474Phe replacement and impairs SHMT nuclear transport and subsequent thymidylate synthesis (Woeller et al., 2007), was investigated in 105 MDS and 185 control mothers from Brazil, and both 1420CC (OR = 0.35; 95% CI = 0.2–0.6) and 1420CT (OR = 0.2; 95% CI = 0.1–0.4) genotypes resulted in a decreased maternal risk of birth of a child with DS with respect to the 1420TT genotype (Marucci et al., 2012). We investigated two common TYMS polymorphisms in 94 MDS and 113 control mothers of Italian origin (Coppedè et al., 2009), namely a 28-bp short tandem repeats (rs34743033) in the 5′-untranslated region (5′-UTR) that is linked to gene expression levels (Horie et al., 1995), and a 6-bp deletion (1494 ins/del) polymorphism in the 5′-UTR (rs34489327) that affects mRNA stability into the cytoplasm (Ulrich et al., 2002). None of the two studied TYMS polymorphisms resulted an independent maternal risk factor for DS birth, but the combined MTHFR 1298AC/TYMS 28-bp 2R/2R genotype resulted in decreased maternal risk (Coppedè et al., 2009). Concerning the DHFR gene, Mendes and coworkers (2010) genotyped 105 MDS and 185 control mothers from Brazil for the presence of a 19-bp ins/del polymorphism (rs70991108) that was previously linked to alterations in folate metabolism (Kalimbach et al., 2008), but no association with maternal risk of a DS birth was observed (Mendes et al., 2010). Unfortunately, due to the absence of replication studies, none of these polymorphisms can be confirmed or excluded as a maternal risk factor for having a birth with trisomy 21.

**Betaine-homocysteine Methyltransferase (BHMT)**

BHMT is a zinc-dependent protein that catalyzes the synthesis of methionine from the methyl-donor betaine and hcy (Figure 1), thus contributing to the regulation of homocysteine levels, and is particularly active in the liver and in the kidneys (Obeid, 2013). A BHMT 742G>A polymorphism (rs3773890) leads to Arg239Gln substitution and to a slight reduction in enzyme kinetics, that however do not appear to alter circulating hcy levels (Li et al., 2008). However, three recent case-control studies performed in Brazilian women (Zampieri et al., 2012a; Amorim et al., 2013) suggest that carriers of the BMTH 742A allele, and particularly homozygous 742AA carriers, are at decreased maternal risk of birth of a child with DS than 742GG carriers (Table 1), making this gene a valuable candidate for further investigation.

**DNA Methyltransferase 3B (DNMT3B)**

In their pioneering studies James et al. (1999) and Hobbs et al. (2000) advanced the hypothesis that polymorphisms of folate pathway genes could result in altered methylation of chromosome 21 peri-centromeric regions, favoring its malsegregation during maternal meiosis. Particularly, to support a causal association between DNA hypomethylation, peri-centromeric decondensation, and abnormal chromosome segregation, Hobbs et al. (2000) reported the example of the monogenic disease, Immunodeficiency, Centromeric instability and Facial anomalies (ICF) syndrome, which is a Mendelian disorder associated with DNMT3B mutations and DNA methylation defects of satellite and non-satellite regions (Hobbs et al., 2000). Despite that a direct evidence of a link between
folate pathway gene polymorphisms and DNA methylation levels of chromosome 21 peri-centromeric regions has not yet been demonstrated, two recent genetic association studies suggest that promoter polymorphisms of the DNMT3B gene might be associated with the maternal risk of birth of a child with DS (Coppedè et al., 2013b; Jaiswal et al., 2015). DNMT3b is a de novo DNA methyltransferase that localizes primarily to the nucleus, and is required for the regulation of DNA methylation at centromeric and peri-centromeric regions of human chromosomes (Gopalakrishnan et al., 2009). DNMT3B promoter polymorphisms, namely -149C>T (rs2424913) and -579G>T (rs1569686), are in strong linkage disequilibrium, give rise to functional haplotypes that could impair protein expression levels, and have been associated to various kinds of human cancers (Zhu et al., 2012). We genotyped 172 MDS and 157 control mothers of Italian origin observing a decreased risk of birth of a child with DS of the DNMT3B -579T allele, with respect to GG carriers; moreover, the combined DNMT3B -579GT/149CC genotype was associated with an even more significant reduced maternal risk of birth of a child with DS (Table 1) (Coppedè et al., 2013b). More recently, a similar study performed in 150 Indian MDS and 172 control mothers revealed a significant increased frequency of the DNMT3B -579G/-149T haplotype in the MDS group (Jaiswal et al., 2015). Overall, both studies suggest that combinations of DNMT3B promoter polymorphisms might be associated to the maternal risk for having a birth with trisomy 21, however data are still preliminary and should be confirmed in future studies.

**Gene-gene Interactions**

Table 1 clearly shows that many authors reported an increased maternal risk of birth of a child with DS for carriers of combined genotypes given by the presence of two simultaneous risk alleles, mainly combinations of MTHFR 677T and 1298C alleles, or combinations of MTHFR 677T and MTRR 66G ones (Table 1). However, when authors searched for the simultaneous presence of more than two risk alleles, they often reported increased maternal risk for a DS birth with the increasing number of variants in folate pathway genes carried by the mother: for example, da Silva et al. (2005) observed that MDS tend to present more variant alleles than control mothers among MTHFR 677C>T, MTHFR 1298A>C, MTR 2756A>G, MTRR 66A>G, and CBS 844ins68 polymorphisms, and the presence of each uncommon allele was associated with an increment of 25.9% in the risk of a DS pregnancy (da Silva et al., 2005). Similarly, Biselli et al. (2008b) observed that the presence of three or more variant alleles among MTHFR 677C>T, MTHFR 1298A>C, MTR 2756A>G, and RFC1 80G>A, resulted in a 1.7-fold increase in maternal risk for a DS birth (Biselli et al., 2008b), while Brandalize et al. (2010) analyzed the genotypes generated by the following polymorphisms: MTR 2756A>G, MTRR 66A>G, CBS 844ins68, and RFC1 80G>A, observing that the OR for having a child with DS ranged from 4.8 to 6.9 depending on the number of risk genotypes considered (Brandalize et al., 2010). We used artificial neural networks (ANNs) to discriminate between MDS and control mothers using genotyping data and the frequency of chromosome damage and malsegregation in peripheral lymphocytes evaluated by means of the micronucleus assay (Coppedè et al., 2010). ANNs revealed that micronucleus frequency and genotyping data for MTHFR 677C>T, TYMS 28bp repeats, TYMS 1494 6bp ins/del, MTR 2756A>G, and RFC1 80G>A polymorphisms, allowed to discriminate between MDS and control mothers with 90% accuracy (Coppedè et al., 2010). Overall, those data suggest that the combined presence of several variant alleles of folate pathway genes is likely to increase significantly the maternal risk of birth of a child with DS.

**Gene-nutrient Interactions**

In their pioneering study James et al. (1999) not only observed an increased frequency of MTHFR 677CT and TT genotypes, but also increased hcy levels, and association of those genotypes with increased hcy levels in MDS with respect to control mothers. Furthermore, the authors noticed an impaired hcy/methionine conversion, was higher in MDS than in control mothers (James et al., 1999). Overall, the authors suggested complex gene-environment interactions at the basis of the maternal susceptibility for the birth of a child with DS, and many others have subsequently measured or estimated biomarkers of one-carbon metabolism in MDS and control mothers, including plasma hcy, plasma or serum folate, vitamin B6 and/or vitamin B12, red blood cell (RBC) folate, and related micronutrients, searching for association with the genetic polymorphisms of folate pathway genes (Table 3). Despite that those studies are often conflicting, most of them reported increased hcy levels or decreased measured or estimated folates in MDS with respect to control mothers (Table 3), and several authors observed association with the studied polymorphisms, including MTHFR 677C>T and 1298A>C polymorphisms that were often associated with increased hcy levels (James et al., 1999; O'Leary et al., 2002; da Silva et al., 2005; Martínez-Frías et al., 2006; Wang et al., 2007; Biselli et al., 2008b; Zampieri et al., 2012b). Similarly, the MTRR 66A>G polymorphism was linked to MMA levels, an indicator of the vitamin B12 status (Zampieri et al., 2012b), with hcy levels in interaction with the MTHFR 1298A>C polymorphism (Martínez-Frías et al., 2006), and with both folate and hcy levels in combination with the MTR 2756A>G one (Coppedè et al., 2014). The MTRR 524C>T polymorphism was associated with reduced hcy levels in carriers of the MTRR 524TT genotype (Wang et al., 2013a), and the RFC1 80G>GG genotype was associated with high plasma folate levels in women aged 35 years or less at conception (Zampieri et al., 2012b). In summary, all the three genetic polymorphisms (MTHFR 677C>T, MTRR 66A>G, and RFC1 80G>A) which have been linked to the maternal risk for the birth of a child with DS by literature meta-analyses (Table 2), and other polymorphisms in the same genes (MTHFR 1298A>C and MTRR 524C>T), have been associated with hematocentral markers of one-carbon metabolism (Table 3). Limitations of those studies, that could also partially account for the conflicting nature of the findings, include the fact that in most of the cases the hematocentral markers have been measured after
the maternal risk for having a child with DS were published (Hobbs et al., 2000). However, as discussed in Section "The women enrolled in those studies were mainly collected from 1989 between the studied polymorphisms and maternal risk for DS, therefore, despite that both observed significant associations available North American studies addressing the contribution (Castilla et al., 2003; Goh et al., 2006). Unfortunately, the two in other countries after fortifying wheat flour with folic acid reducing the birth prevalence of DS individuals (Simmons et al., 2010). Quite recently, a population-based case-control study, which included 1.011 MDS that reported their use of supplements containing folic acid at peri-conception, showed that lack of maternal folic acid supplementation was more frequent among infants with DS and AVSD (OR = 1.69; 95% CI = 1.08–2.63) or atrial septal defects (OR = 1.69; 95% CI = 1.11–2.58) than among infants with DS and no heart defect, suggesting that lack of maternal folic acid supplementation is associated with septal defects in infants with DS (Bean et al., 2011). Unfortunately, or atrial septal defects (OR = 1.69; 95% CI = 1.11–2.58) than among infants with DS and no heart defect, suggesting that lack of maternal folic acid supplementation is associated with septal defects in infants with DS (Bean et al., 2011). Unfortunately, only a few case-control studies have been conducted so far to evaluate polymorphisms in folate-pathway genes as risk factors for CHD occurrence in a DS birth (listed in Table 4), and no meta-analysis of the data is yet possible. Brandalize et al. (2009) genotyped 239 Brazilian MDS for MTHFR 677C>T and 1298A>C polymorphisms, including 90 mothers of a DS child with CHD (DS-CHD) and 149 mothers of a DS child without CHD. The authors observed that MDS carriers of the MTHFR
peri-conception, the risk for DS-CHD remained significant only in those with MTHFR 677CT or TT genotype that did not take folic acid supplements (OR = 2.07; 95% CI = 1.18–3.61). However, when MDS were stratified according to folic acid supplementation at peri-conception, the risk for DS-CHD remained significant only in those with MTHFR 677CT or TT genotype that did not take folic acid supplements (OR = 2.26; 95% CI = 1.25–4.09), but was lost in those MDS that used folic acid supplements at peri-conception (OR = 1.07; 95% CI = 0.20–5.68). No association with DS-CHD risk was observed for the MTHFR 1298A>C polymorphism (Brandalizé et al., 2009). Locke et al. performed a case-control study in a group of 121 American case families (mother, father, and proband with DS and AVSD) and 122 American control families (mother, father, and proband with DS and no CHD), all genotyped for 45 polymorphisms in MTHFR, MTR, MTRR, RFC1, and CBS genes, observing that several RFC1 polymorphisms, all in strong linkage with the RFC1 80G>A one, showed nominally significant associations with AVSD, with ORs of between 1.34 and 3.78. In addition, the MTHFR 1298A allele was over-transmitted to DS individuals with AVSD and under-transmitted to those with no CHD (Locke et al., 2010). By contrast, Božović et al. (2011) genotyped 112 DS subjects (54 with CHD and 58 without CHD) and 221 matched controls from Croatia for both MTHFR 677C>T and 1298A>C polymorphisms, observing no difference in allele or genotype frequencies for both polymorphisms between DS-CHD cases and DS cases without CHD, or between DS cases and healthy controls (Božović et al., 2011). Furthermore, the authors genotyped 107 MDS and 34 complete parent–offspring triads. No association was observed between the presence of either MTHFR 677C>T or MTHFR 1298A>C polymorphism in the mother and risk of DS-CHD offspring, and all MDS did not use folic acid supplements at peri-conception; similarly, the allele transmission of the two MTHFR polymorphisms showed no deviations from random segregation, leading the authors to conclude that none of the studied polymorphisms was associated with CHD risk in their cohort (Božović et al., 2011). More recently, Elsayed et al. (2014) genotyped 61 Egyptian mothers of children with septal defects (25 with DS and 36 without DS) and 61 control mothers (with no children with DS or CHD) who did not receive folic acid supplementation in the peri-conceptional period. All women were genotyped for the MTHFR 677C>T polymorphism, and the MTHFR 677CT genotype resulted significantly higher in mothers of DS with atroventricular (AV) canal compared to control mothers (OR: 1.21, 95% CI: 1.02–1.43). Collectively those papers are conflicting but four out of five of them (Brandalizé et al., 2009; Locke et al., 2010; Bean et al., 2011; Elsayed et al., 2014) suggest a possible contribution of folate metabolism to the development of CHD in DS individuals. Despite that a meta-analysis of the few studies of DS-CHD is yet not possible due to their relatively small number (Table 4), a recent meta-analysis of 18 case-control studies, that included data from 18,500 cases of CHD, revealed that maternal folic acid supplementation is associated with a significant decreased risk of CHD (OR: 0.72, 95% CI: 0.63–0.82), and the association remained significant even after stratification of the data into CHD subtypes (Feng et al., 2015). Similarly, recent literature meta-analyses of non DS-CHD cases revealed association of maternal MTHFR 677C>T and MTRR 66A>G polymorphisms with CHD risk in the offspring (Wang et al., 2013c; Cai et al., 2014), leading authors to hypothesize that methylation profiles and other epigenetic abnormalities could contribute to the etiology of heart malformations.

In this regard, Obermann-Borst et al. (2011) performed a study in 143 Dutch children with CHD and 186 healthy children, observing that in the overall CHD group, blood SAM levels, serum folate, and RBC folate levels were significantly higher in the controls. However, when the analysis was restricted to the subgroup of children with DS-CHD, they showed significantly lower SAM:SAH ratio (the DNA methylation potential) than other CHD cases, suggesting that cases of DS-CHD may be associated with global hypomethylation (Obermann-Borst et al., 2011). A recent study was performed to explore the global methylation profile of fetal heart DNA from 22 medically terminated pregnancies (4 with normal development, 6 with DS-CHD, 6 with DS without CHD, and 6 with isolated CHD) in comparison to blood DNA from 656 subjects (Serra-Juhé et al., 2015). The study revealed remarkably different profiles between tissues, with 407 genes hypomethylated in heart tissue compared to blood, and 339 genes hypomethylated in blood compared to heart tissue. Among the 22 heart DNA samples significant differences in DNA methylation profiles were seen between fetuses with DS and fetuses with a normal karyotype. The comparison of individual DS-CHD cases with two control groups (normal development and DS without CHD) revealed 19 differentially methylated regions. Several epimutations were detected in candidate genes involved in growth regulation, apoptosis and folate pathway in cases of syndromic and isolated CHD, providing evidence that impaired DNA methylation occurred in their developing heart tissue, likely contributing to the onset of CHD (Serra-Juhé et al., 2015).

Discussion and Conclusions

Despite that DS occurs in almost 1 on 700 live births, the molecular mechanisms leading to maternal chromosome 21 malsegregation during oogenesis are still not fully understood. Since 1999, it was suggested that maternal polymorphisms in folate pathway genes could contribute to the epigenetic regulation of the chromatin structure in those regions, thus acting as maternal risk factors for the birth of a child with DS (James et al., 1999). That hypothesis stimulated considerable research over the last 15 years, leading to the production of more than 50 case-control studies that, despite the conflicting nature of their results, revealed a complexity of gene-gene and gene-nutrient interactions in folate metabolism as potential maternal risk factors for having a birth with trisomy for chromosome 21 (Table 1). More recent meta-analyses of those studies have revealed that at least three of the most frequently studied polymorphisms, namely MTHFR 677C>T, MTRR 66A>G, and RFC1 80G>A, could act as weak independent maternal risk factors for having a child with DS, with slight differences among populations likely due to the existence of complex gene-gene and gene-environment interactions (Table 2). Limitations of those studies lies mainly in the fact that, with the exception of the
most frequently studied MTHFR 677C>T polymorphism for which data on over 3,000 MDS and almost 5,000 control mothers were available for meta-analysis (Rai et al., 2014), data on all the other polymorphisms are available for less than 2,000 MDS, and often less than 1,000 MDS, limiting the power to detect association also during meta-analysis (Table 2). Furthermore, data concerning the occurrence of the meiotic error (MI or MII), the maternal age at conception, as well as smoking and drinking habits, are often unavailable in case-control studies, making it impossible to evaluate their contribution during the meta-analysis (Table 2). However, taking collectively the literature produced so far in this field, we can argue that there is substantial evidence indicating that maternal impairments in folate metabolism could favor at least certain errors leading to chromosome 21 malsegregation; but considering that maternal meiosis in a female starts during embryogenesis, the contribution of the maternal grandmother’s folate intake is still a matter of debate (Coppeè, 2009).

Furthermore, overexpression of folate pathway genes mapping to chromosome 21 in a developing DS embryo could result in a different requirement of dietary folates with respect to a normal embryo and, if not properly provided by the maternal diet, could contribute to death in utero, impaired growth and, if the birth is reached, to epigenetic changes of several genes likely contributing to the onset of either congenital defects or other diseases in adult-life (Martinez-Frias et al., 2006). Unfortunately, our understanding of this is still in its infancy, due to scarce availability of comparison data between women who experience loss of trisomy 21 pregnancies and those with trisomic fetuses that survive up to the birth, as well as to a few epigenetic studies in DS individuals. In this regard, evidence is accumulating concerning the possible contribution of impaired maternal folate metabolism and epigenetic changes during embryogenesis to the occurrence of DS-CHD cases (Table 4). We cannot exclude that similar mechanisms could also account for other DS comorbidities, but data are still scarce or missing. For example, Brandalize et al. (2009) investigated whether or not maternal MTHFR polymorphisms could account also for the occurrence of congenital gastrointestinal disease in DS births observing no association (Table 4), but they only had 16 DS cases with gastrointestinal disease in their cohort (Brandalize et al., 2009). Similarly, recent studies in DS individuals suggest that epigenetic deregulation of several genes could not only account for CHD (Serra-Juhé et al., 2015), but also for other complications such as learning and memory deficits (Dekker et al., 2014) or accelerated aging (Horvath et al., 2015), but how much of this results from in utero exposure is still unclear.

In conclusion, the available literature in this field suggests that it is now time for the design of large-scale prospective studies, spanning over at least three different generations, in order to clarify the possible contribution of both maternal and maternal grandmother’s diet and genotype to the occurrence of meiotic errors favoring chromosome 21 malsegregation and the birth of a DS child, as well as to other metabolic changes and/or epigenetic modifications leading to death in utero or to the occurrence of either congenital or age-related DS comorbidities.

Acknowledgments

This work was not supported by research grants and publication costs were entirely covered by the author. The author acknowledges all MDS and control mothers that took part in the studies described in this review making it possible to advance the scientific knowledge in this field. The author also acknowledges the devotion and the scientific contribution of all the authors of the papers discussed in this review article, and encourages them to continue their work in such a complex but increasingly fascinating field.

References

Acácio, G. L., Barini, R., Bertuzzo, C. S., Couto, E. C., Annichino-Bizzacchi, J. M., and Júnior, W. P. (2005). Methylenetetrahydrofolate reductase gene polymorphisms and their association with trisomy 21. Prenat. Diagn. 25, 1196–1199. doi:10.1002/pd.1296

Amorim, M. R., and Lima, M. A. (2013). MTRR 66A>G polymorphism as maternal risk factor for Down syndrome: a meta-analysis. Genet. Test Mol. Biomarkers 17, 69–73. doi:10.1089/gtmb.2012.0200

Amorim, M. R., Moura, C. M., Gomes, A. D., Barboza, H. N., Lopes, R. B., Ribeiro, M. G., et al. (2013). Betaine-homocysteine methyltransferase 742G>A polymorphism and risk of down syndrome offspring in a Brazilian population. Mol. Biol. Rep. 40, 4685–4689. doi:10.1007/s11033-013-2563-x

Balduino Victiorino, D., de Godoy, M. F., Goloni-Bertollo, E. M., and Pavarino, E. C. (2014). Genetic polymorphisms involved in folate metabolism and maternal risk for down syndrome: a meta-analysis. Di. Markers 2014:517504. doi:10.1155/2014/517504

Barua, S., Kuizon, S., and Junaid, M. A. (2014). Folic acid supplementation in pregnancy and implications in health and disease. J. Biomed Sci. 21:77. doi:10.1186/s12929-014-0077-z

Bean, L. I., Allen, E. G., Tinker, S. W., Hollis, N. D., Locke, A. E., Druschel, C., et al. (2011). Lack of maternal folic acid supplementation is associated with heart defects in Down syndrome: a report from the National Down Syndrome Project. Birth Defects Res. A Clin. Mol. Teratol. 91, 885–893. doi:10.1002/bdra.22848

Beetstra, S., Thomas, P., Salisbury, C., Turner, J., and Fenech, M. (2005). Folic acid deficiency increases chromosomal instability, chromosome 21 aneuploidy and sensitivity to radiation-induced micronuclei. Mutat. Res. 578, 317–326. doi:10.1016/j.mrfmmm.2005.01.012

Biselli, J. M., Brumatti, D., Frigeri, V. F., Zampieri, B. L., Goloni-Bertollo, E. M., and Pavarino-Bertelli, E. C. (2008a). A80G polymorphism of reduced folate carrier 1 (RFC1) and C776G polymorphism of transcobalamin 2 (TC2) genes in Down’s syndrome etiology. Sao Paulo Med. J. 126, 329–332. doi:10.1590/S1516-31802008000600007

Biselli, J. M., Goloni-Bertollo, E. M., Zampieri, B. L., Haddad, R., Eberlin, M. N., and Pavarino-Bertelli, E. C. (2008b). Genetic polymorphisms involved in folate metabolism and elevated plasma concentrations of homocysteine: maternal risk factors for Down syndrome in Brazil. Genet. Mol. Res. 7, 33–42. doi:10.4238/vol7-1gmr388

Blom, H. J., and Smulders, Y. (2011). Overview of homocysteine and folate metabolism. With special references to cardiovascular disease and neural tube defects. J. Inherit. Metab. Dis. 34, 75–81. doi:10.1007/s10545-010-9177-4

Bodurogu, K., Alany, Y., Koldan, B., and Tunçbilek, E. (2004). Methylenetetrahydrofolate reductase enzyme polymorphisms as maternal risk for Down syndrome among Turkish women. Am. J. Med. Genet. A. 127A, 5–10. doi:10.1002/ajmg.a.20432
Coppedè, I. B., Vraneković, J., Cizmarević, N. S., Mahulja-Stamenković, V., Prpić, I., and Brajenović-Milicić, B. (2011). MTHFR C677T and A1298C polymorphisms as a risk factor for congenital heart defects in Down syndrome. Pediatric. Int. 53, 546–550. doi: 10.1111/j.1442-200X.2010.03310.x

Bralandize, A. P., Bandinelli, E., dos Santos, P. A., and Schüler-Faccini, L. (2010). Maternal gene polymorphisms involved in folate metabolism as risk factors for Down syndrome offspring in Southern Brazil. Dis. Markers 29, 95–101. doi: 10.1155/2010/250324

Bralandize, A. P., Bandinelli, E., dos Santos, P. A., Roisenberg, I., and Schüler-Faccini, L. (2009). Evaluation of C677T and A1298C polymorphisms of the MTHFR gene as maternal risk factors for Down syndrome and congenital heart defects. Am. J. Med. Genet. A 149A, 2080–2087. doi: 10.1002/ajmg.a.32989

Cai, B., Zhang, T., Zhong, R., Zou, L., Zhu, B., Chen, W., et al. (2014). Genetic variant in MTRR, but not MTR, is associated with risk of congenital heart disease: an integrated meta-analysis. PLoS ONE 9:e89609. doi: 10.1371/journal.pone.0089609

Canfield, M. A., Collins, J. S., Bottor, L. D., Williams, L. J., Mai, C. T., Kirby, R. S., et al. (2005). Changes in the birth prevalence of selected birth defects after grain fortification with folic acid in the United States: findings from a multi-state population-based study. Birth Defects Res. A Clin. Mol. Teratol. 73, 679–689. doi: 10.1002/bdra.20210

Castilla, E. E., Orioli, I. M., Lopez-Camelo, J. S., Dutra Mda, G., Nazer-Herrera, J., and Latin American Collaborative Study of Congenital Malformations (ECLAMC) (2003). Preliminary data on changes in neural tube defect prevalence rates after folic acid fortification in South America. Am. J. Med. Genet. A 123A, 123–128. doi: 10.1002/ajmg.a.20230

Chadeaufex-Kevemans, B., Coudé, M., Muller, F., Oury, J. F., Chabli, A., Jais, J., et al. (2002). Methylene-tetrahydrofolate reductase polymorphism in the etiology of Down syndrome. Pediatr. Res. 51, 766–767. doi: 10.1203/00006450-200206000-00018

Chango, A., Emery-Fillon, N., de Courcy, G. P., Lambert, D., Pfister, M., Rosenblatt, D. S., et al. (2000). Folate deficiency and folate carrier gene and its associations with folate status and homocysteinaemia. Mol. Genet. Metab. 70, 310–315. doi: 10.1006/mgme.2000.3034

Chango, A., Fillon-Emery, N., Mircher, C., Bléhaut, H., Lambert, D., Herbeth, B., et al. (2005). No association between common polymorphisms in genes of folic acid and homocysteine metabolism and the risk of Down’s syndrome among French mothers. Br. J. Nutr. 94, 166–169. doi: 10.1079/BJ20051490

Choi, J. H., Yates, Z., Veysey, M., Heo, Y. R., and Lucock, M. (2014). Contemplary issues surrounding folic acid fortification initiatives. Prev. Nutr. Food Sci. 19, 247–260. doi: 10.3746/pnfs.2014.19.4.247

Coppedè, F. (2009). The complex relationship between folate/homocysteine metabolism and risk of Down syndrome. Mutat. Res. 682, 54–70. doi: 10.1016/j.mrrrev.2009.06.001

Coppedè, F., Bosco, P., Lorenzoni, V., Denaro, M., Anello, G., Antonucci, I., et al. (2014). The MTRR 66A>G polymorphism and maternal risk of birth of a child with Down syndrome in Caucasian women: a case-control study and a meta-analysis. Mol. Biol. Rep. 41, 5571–5583. doi: 10.1007/s11033-014-3462-5

Coppedè, F., Bosco, P., Lorenzoni, V., Miglieli, F., Barone, C., Antonucci, I., et al. (2013a). The MTR 2756A>G polymorphism and maternal risk of birth of a child with Down syndrome: a case-control study and a meta-analysis. Mol. Biol. Rep. 40, 6913–6925. doi: 10.1007/s11033-013-2810-1

Coppedè, F., Bosco, P., Tannorella, P., Romano, C., Antonucci, I., Stuppa, L., et al. (2013b). DNMT3B promoter polymorphisms and maternal risk of birth of a child with Down syndrome. Hum. Reprod. 28, 545–550. doi: 10.1093/humrep/des376

C appréde, F., Calloler-Fouf, M., Battaglia-Hsu, S., Albert, J. M., Freund, J. N., Dulluc, I., et al. (2013). Molecular and cellular effects of vitamin B12 in brain, myocardium and liver through its role as co-factor of methionine synthase. Biochimie 95, 1033–1040. doi: 10.1016/j.biochi.2013.01.020
Guenter, B. D., Sheppard, C. A., Tran, P., Rozen, R., Matthews, R. G., and Ludwig, M. L. (1999). The structure and properties of methylenetetrahydrofolate reductase from Escherichia coli suggest how folate ameliorates human hyperhomocysteinemia. *Nat. Struct. Biol.* 6, 359–365. doi: 10.1038/7594

Hobbs, C. A., Sherman, S. L., Yi, P., Hopkins, S. E., Torfs, C. P., Hine, R. J., et al. (2000). Polymorphisms in genes involved in folate metabolism as maternal risk factors for Down syndrome. *Am. J. Hum. Genet.* 67, 623–630. doi: 10.1086/303055

Hollis, N. D., Allen, E. G., Oliver, T. R., Tinker, S. W., Druschel, C., Hobbs, C. A., et al. (2013). Preconception folic acid supplementation and risk for chromosome 21 nondisjunction: a report from the National Down Syndrome Project. *Am. J. Med. Genet. A.* 161A, 438–444. doi: 10.1002/ajmg.a.35796

Horie, N., Aiba, H., Oguro, K., Hojo, H., and Takeishi, K. (1995). Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. *Cell Struct. Funct.* 20, 191–197. doi: 10.1247/csf.20.191

Horvath, S., Garagnani, P., Bacalini, M. G., Pirazzini, C., Salvioli, S., Gentilini, D., et al. (2015). Accelerated epigenetic aging in Down syndrome. *Aging Cell.* 14, 491–495. doi: 10.1111/acel.12325

Hou, Z., and Matherly, L. H. (2014). Biology of the major facilitative folate transporters. *J. Biomol. Struct. Dyn.* 32, 461–466. doi: 10.3724/SP.J.1005.2010.00461

Kokotas, H., Grigoriadou, M., Mikkelsen, M., Giannoulia-Karantana, A., and Liao, Y. P., Zhang, D., Zhou, W., Meng, F. M., Bao, M. S., Xiang, P., et al. (2014). Combined folate gene MTHFD and TC polymorphisms as maternal risk factors for Down syndrome in China. *Genet Mol. Res.* 13, 1764–1773. doi: 10.4238/2014.March.17.4

Locke, A. E., Dooley, K. J., Tinker, S. W., Cheong, S. Y., Feingold, E., Allen, E. G., et al. (2010). Variation in folate pathway genes contributes to risk of congenital heart defects among individuals with Down syndrome. *Genet. Epidemiol.* 34, 613–623. doi: 10.1002/gepi.20518

Martínez-Frias, M. L. (2008). The biochemical structure and function of methylenetetrahydrofolate reductase provide the rationale to interpret the epidemiological results on the risk for infants with Down syndrome. *Am. J. Med. Genet. A.* 146A, 1477–1482. doi: 10.1002/ajmg.a.32308

Martínez-Frias, M. L., Pérez, B., Desviat, L. R., Castro, M., Leal, F., Rodríguez, L., et al. (2006). Maternal polymorphisms 677T-C and 1298A-C of MTHFR, and 66A-G MTRR genes: is there any relationship between polymorphisms of the folate pathway, maternal homocysteine levels, and the risk for having a child with Down syndrome? *Am. J. Med. Genet. A.* 140, 987–997. doi: 10.1002/ajmg.a.31203

Marucci, G. H., Zampieri, B. L., Biselli, J. M., Valentini, S., Bertollo, E. M., Eberlin, M. N., et al. (2012). Polymorphism C1420T of Serine hydroxymethyltransferase gene on maternal risk for Down syndrome. *Mol. Biol. Rep.* 39, 2561–2566. doi: 10.1007/s11033-011-1008-7

Medica, I., Maver, A., Goncalo Figueiredo, A., and Peterlin, B. (2009). Polymorphisms in genes involved in folate metabolism as maternal risk factors for Down syndrome —meta-analysis. *Cent. Eur. J. Med.* 4, 395–408. doi: 10.2478/s11536-009-0055-0

Meguid, N. A., Dardir, A. A., Khass, M., Hossieny, L. E., Ezzat, A., and El Awady, M. K. (2008). MTHFR genetic polymorphism as a risk factor in Egyptian mothers with Down syndrome children. *Dis. Markers.* 24, 19–26. doi: 10.1155/2008/214027

Mendes, C. C., Biselli, J. M., Zampieri, B. L., Goloni-Bertolo, E. M., Eberlin, M. N., Haddad, R., et al. (2010). 19-base pair deletion polymorphism of the dihydrofolate reductase (DHFR) gene: maternal risk of Down syndrome and folate metabolism. *Sao Paulo Med. J.* 128, 215–218. doi: 10.1590/S1516-31802010000500008

Mohanty, P. K., Kapoor, S., Dubey, A. P., Pandey, S., Shah, R., Nayak, H. K., et al. (2012). Evaluation of C677T polymorphism of the methylenetetrahydrofolate reductase gene and its association with levels of serum homocysteine, folate, and vitamin B12 as maternal risk factors for Down syndrome. *Indian J. Hum. Genet.* 18, 285–289. doi: 10.1007/10397-006-107977

Neagos, D., Cretu, R., Tutulan-Cunita, A., Stoian, V., and Bolhiutea, L. C. (2010a). RFC - 1 Gene polymorphism and the risk of Down Syndrome in Romanian population. *Maedica (Buchar)* 5, 280–285.

Neagos, D., Cretu, R., Tutulan-Cunita, A., Stoian, V., and Bolhiutea, L. C. (2010b). Methylenetetrahydrofolate dehydrogenase (MTHFD) enzyme polymorphism as a maternal risk factor for trisomy 21: a clinical study. *J. Med. Life* 3, 454–457.

Obeid, R. (2013). The metabolic burden of methyl donor deficiency with focus on the betaine homocysteine methyltransferase pathway. *Nutrients* 5, 3481–3495. doi: 10.3390/nut5093481

Obermann-Borst, S. A., van Driei, L. M., Helbing, W. A., de Jonge, R., Wildhagen, M. F., Steegers, E. A., et al. (2011). Congenital heart defects and biomarkers of methylation in children: a case-control study. *Eur. J. Clin. Invest.* 41, 143–150. doi: 10.1111/j.1365-2362.2010.02388.x

O’Leary, V. B., Parle-McDermott, A., Molloy, A. M., Kirke, P. N., Johnson, Z., Conley, M., et al. (2002). MTRR and MTHFR polymorphism: link to Down syndrome? *Am. J. Med. Genet.* 107, 151–155. doi: 10.1002/ajmg.a.10121

Oliver, T. R., Feingold, E., Yu, K., Cheung, V., Tinker, S., Yadav-Shah, M., et al. (2008). New insights into human nondisjunction of chromosome 21 in oocytes. *PLoS Genet.* 4:e1000333. doi: 10.1371/journal.pgen.1000333

Oliver, T. R., Middlebrooks, C. D., Tinker, S. W., Allen, E. G., Bean, L. J., Begum, M. A., et al. (2014). An examination of the relationship between hotspots and recombination associated with chromosome 21 nondisjunction. *PLoS ONE* 9:e99560. doi: 10.1371/journal.pone.0099560

Oliver, T. R., Tinker, S. W., Allen, E. G., Hollis, N., Locke, A. E., Bean, L. J., et al. (2012). Altered patterns of multiple recombinant events are associated with nondisjunction of chromosome 21. *Hum. Genet.* 131, 1039–1046. doi: 10.1007/s00439-011-1121-7
Pandey, S. K., Mohanty, P. K., Polipally, S. K., and Kapoor, S. (2013). Genetic polymorphisms of (677T and 1298C) and homocysteine metabolism as maternal risk factor for Down's syndrome patients in north Indian population. *Int. J. Pharm. Biol. Sci.* 4, 249–256.

Pozi, E., Vergani, P., Dalprà, L., Combi, R., Silvestri, D., Crosti, F., et al. (2009). Maternal polymorphisms for methylenetetrahydrofolate reductase and methionine synthase reductase and risk of children with Down syndrome. *Am. J. Obstet. Gynecol.* 200, 636.e1–636.e6. doi: 10.1016/j.ajog.2008.12.046

Rai, A. K., Singh, S., Mehta, S., Kumar, A., Pandey, L. K., and Raman, R. (2006). *MTHFR C677T* and *A1298C* polymorphisms are risk factors for Down's syndrome in Indian Indians. *J. Hum. Genet.* 51, 278–283. doi: 10.1007/s10038-005-0356-3

Rai, V., Yadav, U., Kumar, P., Yadav, S. K., and Mishra, O. P. (2014). Maternal methylenetetrahydrofolate reductase C677T polymorphism and Down syndrome risk: a meta-analysis from 34 studies. *PLoS ONE* 9:e808552. doi: 10.1371/journal.pone.0080552

Sadiq, M. F., Al-Refaie, E. A., Al-Nasser, A., Khassawneh, M., and Al-Batayneh, Q. (2011). Methylenetetrahydrofolate reductase polymorphisms C677T and A1298C as maternal risk factors for Down syndrome in Jordan. *Genet. Test Mol. Biomarkers* 15, 51–57. doi: 10.1089/gtmb.2010.0057

Santos-Rebouças, C. B., Corrêa, J. C., Bonomo, A., Fintelman-Rodrigues, N., Moura, K. C., Rodrigues, C. S., et al. (2008). The impact of folate pathway polymorphisms combined to nutritional deficiency as a maternal predisposition factor for Down syndrome. *Dis. Markers* 25, 149–157. doi: 10.1155/2008/487023

Scala, L., Granese, R., Sellitto, M., Salomé, S., Sammartino, A., Pepe, A., et al. (2006). Analysis of seven maternal polymorphisms of genes involved in homocysteine/folate metabolism and risk of Down syndrome offspring. *Genet. Med.* 8, 409–416. doi: 10.1097/GIM.000022806.21793.82

Serra-Juhó, C., Ciscú, I., Homs, A., Flores, R., Torán, N., and Pérez-Jurado, L. A. (2015). DNA methylation abnormalities in congenital heart disease. *EpiGenetics* 10, 167–178. doi: 10.1007/s12829-014-0059-6

Shao, Y., Zhang, C. G., and Cui, J. H. (2005). Association of plasma homocysteine with maternal polymorphisms of genes involved in folate metabolism and risk of Down syndrome offspring. *Zhonghua Yi Xue Yi Chuan Xue Za Zhi* 24, 533–537.

Shao, X., Thomas, P., Xue, J., and Fenech, M. (2004). Folate deficiency induces aneuploidy in human lymphocytes in vitro—evidence using cytogenisis-blocked cells and probes specific for chromosomes 17 and 21. *Mutat. Res.* 551, 167–180. doi: 10.1016/j.mrmm.2003.04.008

Warren, A. C., Chakravarti, A., Wong, C., Slaugenhaupt, S. A., Halloran, S. L., Watkins, P. C., et al. (1987). Evidence for reduced recombinaction on the nondisjoinoned chromosomes 21 in Down syndrome. *Science* 237, 652–654. doi: 10.1126/science.2955519

Weijerman, M. E., and de Winter, J. P. (2010). Clinical practice. The care of children with Down syndrome. *Eur. J. Pediatr.* 169, 1445–1452. doi: 10.1007/s00431-010-1250-8

Woeller, C. F., Anderson, D. D., Szelenyi, D. M., and Stover, P. J. (2007). Evidence for small ubiquitin-like modifier-dependent nuclear import of the thymidylate biosynthesis pathway. *J. Biol. Chem.* 282, 17623–17631. doi: 10.1074/jbc.M702526200

Wu, X., Wang, X., Chan, Y., Jia, S., Luo, Y., and Tang, W. (2013). Folate metabolism gene polymorphisms *MTHFR C677T* and *A1298C* as maternal risk factors for Down syndrome offspring: a meta-analysis. *Eur. J. Obstet. Gynecol. Reprod. Biol.* 167, 154–159. doi: 10.1016/j.ejogrb.2012.11.022

Yang, M., Gong, T., Lin, X., Li, G., Guo, Y., Cao, Z., et al. (2013). Maternal gene polymorphisms involved in folate metabolism and the risk of having a Down syndrome offspring: a meta-analysis. *Mutagension* 28, 661–671. doi: 10.1093/mutagene/geu045

Zampieri, B. L., Biselli, J. M., Goloni-Bertollo, E. M., and Pavarino, E. C. (2012a). *BHMT G742A* and *MTHFD1 G1958A* polymorphisms and Down syndrome risk in the Brazilian population. *Genet. Test Mol. Biomarkers* 16, 628–631. doi: 10.1089/gtmb.2011.0257

Zampieri, B. L., Biselli, J. M., Goloni-Bertollo, E. M., Vannucchi, H., Carvalho, V. M., Cordeiro, J. A., et al. (2012b). Maternal risk for Down syndrome is modulated by genes involved in folate metabolism. *Dis. Markers* 32, 73–81. doi: 10.1155/2012/693864

Zheng, S., Zhang, H., Tang, Y., Liu, P., and Wang, J. (2012). *DNMT3B* polymorphisms and cancer risk: a meta-analysis of 24 case-control studies. *Mol. Biol. Rep.* 39, 4429–4437. doi: 10.1007/s10033-011-1231-2

Zintzaras, E. (2007). Maternal gene polymorphisms involved in folate metabolism and risk of Down syndrome offspring: a meta-analysis. *J. Hum. Genet.* 52, 943–953. doi: 10.1007/s10038-007-0202-x

**Conflict of Interest Statement:** The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2015 Coppede. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.